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1 RESEARCH SUMMARY 
IFI16, a nuclear pathogenic DNA sensor induced by several pro-inflammatory 
cytokines, is a multifaceted protein with various functions. It is also a target for 
autoantibodies as specific antibodies have been demonstrated in the sera of 
patients affected by systemic autoimmune diseases. Following transfection of 
virus-derived DNA, or treatment with UVB, IFI16 delocalizes from the nucleus to 
the cytoplasm and is then eventually released into the extracellular milieu. In this 
PhD research study, using an in-house capture enzyme-linked immunosorbent 
assay we demonstrate that significant levels of IFI16 protein can also exist as 
circulating form in the sera of autoimmune patients. We also show that the rIFI16 
protein, when added in-vitro to endothelial cells, does not affect cell viability, but 
severely limits their tubulogenesis and transwell migration activities. These 
inhibitory effects are fully reversed in the presence of anti-IFI16 N-terminal 
antibodies, indicating that its extracellular activity resides within the N-terminus. It 
was further demonstrated that endogenous IFI16 released by apoptotic cells bind 
neighboring cells in a co-culture. Immunofluorescence assays revealed existence of 
high-affinity binding sites on the plasma membrane of endothelial cells. Free 
recombinant IFI16 binds these sites on HUVEC with dissociation constant of 2.7nM, 
radioiodinated and unlabeled IFI16 compete for binding sites, with inhibition 
constant (Ki) of 14.43nM and half maximal inhibitory concentration (IC50) of 
67.88nM; these data allow us to estimate the presence of 250,000 to 450,000 
specific binding sites per cell. Corroborating the results from functional assays, this 
binding could be completely inhibited using anti-IFI16 N-terminal antibody, but not 
with an antibody raised against the IFI16 C-terminal. By qPCR analysis, we were 
able to identify the cytokine stimulating activity of IFI16. IFI16 treatment on 
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primary endothelial cells lead to time-dependent increased m-RNA expression of 
various chemokines like IL-8, CCL2, CCL5, CCL20, adhesion molecules like ICAM1, 
VCAM1 and TLRs such as TLR3, TLR4 and TLR9. Such pro-inflammatory cytokine 
expression was mediated by Nf-κB dependent pathways. Altogether, these data 
demonstrate that IFI16 may exist as circulating protein in the sera of autoimmune 
patients which binds endothelial cells causing damage and stimulates the 
production of pro-inflammatory cytokines, suggesting a new pathogenic, DAMP-
like alarmin function through which this protein triggers the development of 
autoimmunity.  
IFI16 is highly implicated for its role in inflammasome signaling and DNA sensing, 
while in turn it acts as restriction factor for viral replication. Intracellular viral DNA 
sensors and restriction factors are critical components of host defence, which 
alarm and sensitize immune system against intruding pathogens. Recently 
demonstrated by Gariano GR et.al. PLoS Paths 2012, that the DNA sensor IFI16 
restricts HCMV replication by down-regulating viral early and late but not 
immediate-early mRNAs and their protein expression. However, viruses are known 
to evolve numerous strategies to cope and counteract such restriction factors and 
neutralize the first line of host defense mechanisms. Our findings as described in 
the attached second manuscript, that during early stages of infection, IFI16 
successfully recognizes HCMV DNA. However, in late stages HCMV mislocalizes 
IFI16 into the cytoplasmic viral assembly complex (AC) and finally entraps the 
protein into mature virions. This work clarifies the mechanisms HCMV relies to 
overcome intracellular viral restriction, which provides new insights about the 




 The outcomes of above discussed aspects of IFI16 related research are 
discussed wholly in the attached manuscripts as listed below: 
1. Gugliesi F*, Bawadekar M*, De Andrea M, Dell’Oste V, Caneparo V, Gariglio M 
and Landolfo S. Nuclear DNA Sensor IFI16 as Circulating Protein in Autoimmune 
Diseases Is a Signal of Damage that Impairs Endothelial Cells through High-
Affinity Membrane Binding. PLoS ONE, 2013, 8(5): e63045. 
doi:10.1371/journal.pone.0063045 (* Contributed Equally). 
 
2. Dell’Oste V, Gatti D, Gugliesi F, De Andrea M, Bawadekar M, Lo Cigno I, Biolatti 
M, Vallino M, Marschall M, Gariglio M and Landolfo S. Early stage IFI16 
cytoplasmic translocation and late stage entrapment into egressing virions 






Autoimmunity is a diverse group of disorder that is characterized by the 
production of antibodies that react with host tissues or immune effector cells that 
are autoreactive to endogenous peptides. Autoimmune attack against “self” may 
be involved in the initiation and/or perpetuation of disease. The autoimmune 
processes seem to result, in certain instances, from a normal (or aberrant) immune 
reaction against an exogenous pathogen with subsequent “spreading” of the 
immune response to recognize self-tissue; this reaction can continue in the 
apparent absence of the initiating pathogen. Most often, however, autoimmune 
phenomena are simply phenomenological events (for example, false-positive 
autoantibody tests) without pathogenetic relevance. Autoimmune diseases are 
individually rare, but together they affect approximately 5 percent of the 
population in western countries, with the exception of more commonly occurring 







Figure 1. Factors contributing for 




Many patients with autoimmune disease have increased responsiveness to 
type I IFNs (a/b), and therapy with these cytokines has induced or unmasked 
autoimmune disease in many additional patients [8]. 
2.1.1 Interferons and Autoimmune Disorders 
Interferon (IFN) was first identified in 1957. A protective role against RNA 
viruses was inferred from the ability of viral infections to induce IFN production [9]. 
Subsequently, IFN was found to decrease tumor growth, inflammation, and 
angiogenesis. The existence of many different IFNs was established. IFNs are now 
considered to play key roles in both innate immunity (IFN-α, IFN-β) and adaptive 
immunity (IFN-γ). The IFN pathways are increasingly well understood. These 
pathways are activated in many situations such as defense mechanisms against 
viral and bacterial infections, solid tumors, and hematological malignancies. They 
are also involved in several autoimmune diseases including systemic lupus 
erythematosus (SLE), Sjögren’s syndrome, adult-onset rheumatoid arthritis (RA), 
polymyositis, and systemic sclerosis. Insights gained into the effects of IFNs, 
together with the ability to clone the main IFNs, have led to the development of 
new treatments designed either to support the IFN pathways (hepatitis C and B, 
adjuvant cancer treatment, treatment of some forms of multiple sclerosis) or to 
block the effects of IFNs (SLE). The significance of different IFNs in some common 
autoimmune diseases such as systemic sclerosis (SSc) and Rheumatoid Arthritis 
(RA) is discussed in the following sections. 
Autoimmune rheumatic diseases (AIRD) affect 5-8% of the population with a 
female preponderance and come in two basic flavors: systemic [e.g. Systemic Lupus 
Erythematosus (SLE), Sjogren Syndrome (SjS)], and Systemic Sclerosis (SSc)], and 
organ-specific (e.g. type I diabetes, autoimmune thyroid disease, and multiple 
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sclerosis) diseases. SLE is a disease characterized by a broad spectrum of clinical 
manifestations and a multitude of laboratory abnormalities [10, 11]. In clinical 
practice, the diagnosis of SLE is usually made in a patient who has developed a 
combination of clinical and immunologic features specific to SLE. Similarly, SSc is a 
chronic multisystem autoimmune disease that is highly heterogeneous and has 
multiple overlapping and poorly defined clinical subsets. Primary SjS is considered 
to represent an ideal disease to study the mechanisms underlying autoimmunity 
because its manifestation are both organ specific and systemic in nature. Once 
again, there is no single test for the diagnosis of SjS, and criteria utilizing 
combinations of clinical and laboratory parameters are currently being used. All 
these diseases arise as a consequence of the breakdown in tolerance to self-
antigens, and the diagnosis is also based on the detection of characteristic 
autoantibodies. Those autoantibodies may also be pathogenic reacting with the 
self-antigens in tissues and inducing an inflammatory response that results in 
damage and disease. Glomerulonephritis is one of the commonest and most 
serious manifestations of SLE [11]. Despite the overall improvement in the care of 
SLE in the past two decades, the prognosis of lupus nephritis (LN) remains 
unsatisfactory [12]. Up to 25% of patients still develop end stage renal failure 10 
years after onset of renal disease. Current laboratory markers for LN such as 
proteinuria, urine protein-to-creatinine ratio, creatinine clearance, anti-dsDNA, 
and complement levels are unsatisfactory. They lack sensitivity and specificity for 
differentiating renal activity and damage in lupus nephritis. Besides exploring more 
effective but less toxic treatment modalities that will further improve the remission 
rate, early detection and treatment of renal activity may reduce renal damage. The 
investigation of novel accurate and predictive indexes of AIRD represents a primary 
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goal for the clinical research in this field. Early diagnosis and a better stratification 
of the autoimmune disease process is crucial for an early therapeutic intervention 
which may significantly increase the probability of disease remission and improve 
patient prognosis. Moreover, new diagnostic techniques need to be established 
that can help pathologists recognize histology patterns, correctly diagnose the 
disease, and identify people who are at high risk of developing lethal systemic 
complications. Systemic autoimmune diseases, like SLE, are characterized by the 
production of autoantibodies mainly directed against ubiquitous nuclear targets 
[13]. The skin has long been recognized as a prominent target tissue, with 
cutaneous disease sometimes manifesting de novo after extended exposure to 
sunlight, and established disease being exacerbated by such exposure. Skin lesions 
are present in at least 80% of patients and constitute the primary sign in about 25% 
of these individuals [14, 15]. The microvascular endothelium in SSc and LN is 
severely damaged, basal laminae are usually thickened and reduplicated, and a vast 
number of capillaries are missing or obliterated with the absence of new vessel 
formation. Microvascular endothelial cell (MVEC) injury and apoptosis is a central 
event in the pathogenesis of SSc and LN vasculopathy that leads to microcirculatory 
dysfunction and eventual organ failure. MVEC apoptosis may eventually activate 
the immune-inflammatory system by dendritic cells and macrophage presentation 
of self-antigen present in the apoptotic debris to CD4+ T cells and the subsequent 
triggering of autoantibodies by activated B cells. 
2.1.2 Systemic Sclerosis 
Type I and II IFNs inhibit collagen production both in vivo and in vitro when 
they are added to normal or scleroderma fibroblasts. This effect prompted a 
number of therapeutic trials in patients with diffuse systemic sclerosis, which met 
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with little success. Oddly enough, there have been several reports of systemic 
sclerosis induced by IFN-α therapy for hepatitis C or myeloproliferative diseases or 
by IFN-β therapy for multiple sclerosis. A study of the transcriptome of circulating 
leukocytes from patients with systemic sclerosis showed amplification of mRNAs 
for a few genes involved in the IFN pathway [16], although the IFN signature was 
less typical than in SLE. Serum from patients with systemic sclerosis and 
antitopoisomerase I (Scl70) antibodies induces a higher level of IFN-α production 
by normal peripheral blood mononuclear cells than does serum from patients with 
anticentromere antibody. IFN-α production is higher in patients with diffuse 
systemic sclerosis and in those with interstitial lung disease. Among the genes 
induced by IFN, IFI16 encodes a protein found in large amounts in the epidermis 
and inflammatory dermis of scleroderma lesions. IFI16 plays a role in endothelial 
cell proliferation. An immunohistochemistry study showed an infiltrate of CD123+ 
pDCs in scleroderma-affected skin specimens [17]. In a study of candidate genes, 
increased frequencies of some IRF5 allelic variants were found in patients with 
systemic sclerosis, and these variants were significantly associated with interstitial 
lung disease [18]. IRF5 encodes a transduction protein involved in the pro-
inflammatory cytokine pathway. 
2.1.3 Rheumatoid Arthritis 
Growing evidence indicates that adult-onset RA is a syndrome. In patients who 
produce rheumatoid factor and anticitrullinated protein antibodies (ACPA or anti-
CCP) and who carry a susceptibility allele of the PTPN22 gene and the shared 
epitope of the HLADRB1* alleles, the disease is often erosive and involves TNF-α as 
the key inflammatory cytokine. In another form of RA, there are no rheumatoid 
factors or erosions and the HLA phenotype is often DR3; this form is associated with 
 
12 
several polymorphisms of the IRF5, STAT4 genes encoding transduction proteins 
involved in IFN pathways [19, 20] and of TRAF1, which encodes a negative regulator 
of TNF-α signaling [21]. This form of RA shares similarities with SLE and Sjögren’s 
syndrome, including involvement of IFNs in the inflammatory response. The two 
forms of RA correspond to the model that contrasts two categories of autoimmune 
diseases, one driven by TNF-α and the other by IFN-α [22]. 
2.1.4 Other Autoimmune Diseases 
IFNα/β exert stimulating or inhibitory effects in various autoimmune diseases 
that fall outside the scope of rheumatology. For instance, in type I insulin-
dependent diabetes mellitus, reliable animal models indicate a deleterious role for 
type I IFNs. IFNs are also harmful in multiple sclerosis and its animal model of acute 
encephalitis, and IFN-β is used to treat relapsing/remitting forms of multiple 
sclerosis. Other examples include thyroiditis, some forms of autoimmune 
hemolytic anemia, and some forms of uveitis such as Behçet’s disease uveitis in 
which IFN-α is used to treat flares. 
2.2 ETIOPATHOGENIC ROLE OF TYPE I IFNS IN SYSTEMIC AUTOIMMUNITY 
Since their initial use in the 1980s, IFNs have become an essential component 
of the therapies for many diseases such as hepatitis, multiple sclerosis and some 
hematological malignancies. Although they have been extremely useful in 
conditions that pose therapeutic challenges, complications associated with their 
use have been widely reported, including emerging reports of several autoimmune 
diseases [23-25]. Many patients with autoimmune disease have increased 
responsiveness to type I IFNs (α/β); moreover, therapy with these cytokines has 
been found to induce or unmask autoimmune disease in many patients. Therefore, 
it is now well accepted that IFNs play a critical role in the pathogenesis of several 
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autoimmune diseases, including SLE, SjS, SSc, and type 1 diabetes. In particular, 
long-standing data indicating elevated circulating levels of IFN-α in SLE patients 
have recently been supplemented by gene expression analyses of patient cells 
studied ex vivo, and studies of the induction mechanisms of IFN-α production. 
Administration of recombinant IFN-α, as a therapy for malignancies or hepatitis 
infection, was reported to induce SLE in some cases. More importantly, immune 
complexes bearing anti-nuclear autoantibodies and either RNA or DNA antigens 
have been shown to induce IFN- production. Deregulation of IFN-α in SLE is also 
evident in the gene expression profile of SLE peripheral blood mononuclear cells 
[26-28].  
Gene microarray studies have revealed the upregulation of IFN stimulated 
genes (ISGs) in about half of lupus patients, including genes encoding anti-viral 
proteins, apoptosis regulators, MHC molecules, and chemokines. This "IFN 
signature" is generally associated with active disease states, and renal and CNS 
involvement. Altogether, these findings strongly support a pathogenic role for IFN-
α in SLE. Consistent with these observations, increased expression of IFN-regulated 
genes has been described in the salivary glands of patients affected by Sjogren’s 
syndrome, and plasmacytoid dendritic cells (pDCs) were identified as being the 
main source of IFN-β in these patients [29, 30]. Emerging data have also indicated 
a role for IFNs in the pathogenesis of SSc [16, 31]. Increased mRNA expression of 
two classical ISGs in SSc-affected skin has also been described, namely double-
stranded RNA dependent protein kinase (PKR) and 2’5’-oligoadenylate synthetase 
(2’-5’ OAS) [17]. Our group found an enhanced expression of the IFN-inducible 
protein IFI16 in the epidermis and dermal inflammatory infiltrate obtained from 
SSc and SLE lesions [32]. Altogether, these observations identify type I IFN as the 
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initiator and ISGs as the executioners in the etiopathogenesis of systemic 
autoimmune diseases. As a whole, this finding indicates that similar etiopathogenic 
mechanisms may be involved in different systemic autoimmune diseases and it is 
likely that dysregulation of common molecular pathways will be found across the 
various autoimmune diseases. However, the mechanisms actually driving the 
autoimmune reactions remain elusive, and there are currently no validated 
biomarkers for disease activity or assessment of organ-specific risk.  
2.3 THE INTERFERON-INDUCIBLE P200 (IFI-200) FAMILY OF PROTEINS 
Upon binding to specific receptors, type I IFN lead to the activation of signal 
transduction pathways that activate a broad range of ISGs that are responsible for 
the antiviral, antiproliferative, pro-apoptotic, and immunomodulatory activities of 
type I IFN. One family of IFN-inducible genes is the HIN-200/Ifi-200 gene family, 
which encodes evolutionary related human (IFI16, IFIX, MNDA, and AIM2) and 
murine (Ifi202a, Ifi202b, Ifi203, Ifi204, Ifi205/D3, and Ifi206) proteins [33]. The 
human and murine gene clusters are located on syntenic genomic regions of 
chromosome 1 and probably stem from repeated gene duplications of one 
ancestral gene. The HIN-200 proteins contain at least a 200-amino acid repeat that 
constitutes the HIN domain, which is always near the C-terminus. The common 
domain architecture PYD-HIN of these protein families consists of one or two copies 
of the HIN domain (domains A and B) and an N-terminal PYD domain, also named 
PAAD, DAPIN, or Pyrin, a member of the death domain superfamily [34, 35]. The 
PYD domain, commonly found in cell death-associated proteins such as Pyrin, ASC, 
and zebrafish caspase, is present in the N-terminus of most Ifi200/HIN200 proteins, 




Figure 3: The Mammalian PHYIN Gene Family – Domain Architecture 
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2.4 THE INTERFERON INDUCIBLE 16 (IFI16) PROTEIN 
In the human IFI16 protein, the PYD domain is followed by two copies of a 
HIN domain (A and B respectively). These are separated by a serine-threonine-
proline (S/T/P)-rich spacer region. The size of the spacer region is regulated by 
mRNA splicing and can contain one, two, or three copies of the highly conserved 
56-aa S/T/P domain, giving rise to the isotypic variants IFI16a, IFI16b, and IFI16c 
respectively. A comprehensive bioinformatics analysis revealed the presence of 2 
oligonucleotide/oligosaccharide binding (OB) folds in each HIN domain [39] and 
biophysical approaches demonstrated that the A and B domains of all family 
members, including IFI16, have been implicated in mediating oligonucleotide and 
oligosaccharide binding, protein-protein interactions and dimerization [40].  
 




For example, AIM2 binds dsDNA through its C-terminal oligonucleotide- or 
oligosaccharide binding domain (HIN200 domain), recruits ASC, and triggers 
inflammasome assembly and pro- IL-1b cleavage [41, 42]. More recently, it was 
demonstrated that following the stimulation of cells with transfected DNA, IFI16 
binds to IFN-β stimulated viral DNA and recruits STING. Furthermore, small 
interfering RNA (siRNA) targeted against IFI16 inhibited DNA-induced, but not RNA-
induced, activation of IRF3 and NF-kB, as well as IFN-β induction [43]. Altogether, 
these results demonstrate that PYD-HIN-200 proteins represent a new family of 
innate DNA sensors regulating the early steps of inflammation. The IFI16 nuclear 
phosphoprotein has been demonstrated to recognize foreign DNA and participates 
in the inhibition of cell cycle progression, modulation of differentiation, and cell 
survival [33].  
Figure.5. Schematic diagram indicating the main signaling pathways triggered 
by IFI16 to regulate different cell functions 
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IFI16 was originally identified as a target of interferons (IFN-α/β and -γ), 
however additional triggers have recently been reported that include oxidative 
stress, cell density, and various pro-inflammatory cytokines [44]. IFI16 is expressed 
in hematopoietic cells and in vascular endothelial cells (EC) in blood and lymph 
vessels, suggesting a link between IFI16, angiogenesis and inflammation [3]. In the 
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skin, its expression is normally restricted to the basal proliferative layer, suggesting 
a possible role in the control of skin homeostasis. IFI16 has also been detected in 




Enhanced expression levels of IFI16 were found by the proposing group in 
the epidermis of SLE and SSc patients and in the dermal inflammatory infiltrate 
obtained from patient skin lesions, detected by immunohistochemistry [32]. While 
IFI16 expression is restricted to the basal layer in the normal epidermis from 
healthy subjects, it is greatly increased and ubiquitously expressed in all layers of 
the epidermis in the lesional skin from both SSc (either the limited [lc-] or the 
diffuse [dc-] cutaneous variant) and SLE patients. Furthermore, the dermal 
inflammatory infiltrate shows IFI16 positive staining, indicating that the protein is 
expressed at a high level in lymphocytes, reactive fibroblasts, and EC. This finding 
raises the possibility that local tissue expression of IFI16 (or even its de-localization) 
in epithelial and inflammatory cells can play a role in triggering an autoimmune 
response against this protein. In line with the potential role of IFI16 in these 
autoimmune diseases, lymphocytes as well as fibroblasts and EC can be targets for 
Figure 6. Immunohistochemical detection of IFI16 protein in normal human 
tissues. (A) Exocervix. (B) Exo-endocervix junction. The epithelial cells lining the 
exocervix are positive, but those lining the endocervix are not (arrow). Notice 
that the inflammatory cells strongly expressed IFI16. Nuclei of cells not 
expressing IFI16 are stained blue by counterstain. (C) Vocal cord epithelium. (D) 
Skin. (E) High-power field of IFI16-positive cells showing nucleolar staining 
(arrow). (F) Strong IFI16 immunoreactivity in stromal reactive (upper arrow) and 
endothelial cells (lower arrow). (G) Skin stained with preimmune serum. (H) 
Vocal cord epithelium stained with preimmune serum. Arrows in A, C, D indicate 
IFI16-positive cells. A, B, C, D, G, H, 310. E, 340. F, 320 [3]. 
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autoimmune responses in SLE and SSc, while skin is one of the main tissue targets 
for the clinical manifestations in these patients.  
Molecular studies performed in primary endothelial cells overexpressing 
IFI16 demonstrated that it may be involved in the early steps of inflammation by 
modulating endothelial cell function, such as expression of adhesion molecules and 
chemokine production, cell growth, and apoptosis. Moreover, as previously 
demonstrated that IFI16 expression is induced by proinflammatory cytokines in 
primary endothelial cells [32].  
 
On the other hand, overexpression of nuclear IFI16 protein seems to induce 
pro-inflammatory molecules in endothelial cells which indicates the cytokine 
promoting activity of endogenous nuclear IFI16 [45]. Such overexpressed IFI16 
protein upregulates the production of adhesion molecules like ICAM1, VCAM1 and 
other chemokines like IL-8, MCP1, as shown in the Fig. 8.  





IFI16 has been much implicated on its role in inflammasome signaling. The 
group [43] demonstrates that IFI16 is critical for interferon-β responses upon 
exposure to intracellular cytoplasmic DNA and HSV-1 infection. Furthermore, IFI16 
was shown to directly associate with IFN-β-inducing viral DNA motifs and the 
stimulator of interferon genes (STING). Early studies were unsuccessful in attempts 
to implicate IFI16 in the inflammasome. Specifically, an interaction between ASC 
and IFI16 was not found [46]. Light was shed on this in a study by [47], 
demonstrating that infection of endothelial cells with Kaposi sarcoma-associated 
herpesvirus (KSHV) led to the activation of an ASC-containing inflammasome, with 
a concomitant proteolytic processing of pro-IL-1β that was shown to be dependent 
on IFI16. In addition, the nuclear localization of pro-caspase-1 and ASC prior to 
infection was demonstrated. Cleaved caspase-1 (p20) and ASC were also shown to 
Figure 8: Real time PCR analysis of AdVIFI16-infected HUVEC 
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be in the nucleus at early timepoints of infection followed by the movement of both 
to the cytoplasm at later times of infection with KSHV. Furthermore, by using short 
hairpin RNAs (shRNAs) targeting IFI16 or ASC, they demonstrated that both were 
required for KSHV induced processing of caspase-1 (Figure 9) [47]. IFI16 was found 
to be required for the induction of pro-IL-1β and IL-6 in response to HSV-1, 
highlighting a role for IFI16 in both transcriptional activation as well as the 
inflammasome [43].  




UVB is a well-known stimulus capable of inducing apoptosis in vitro and in 
vivo, and it has been associated with lupus flares [48, 49]. Aberrant IFI16 expression 
in endothelial cells and epithelial cells from the skin, both of which exhibit the main 
clinical manifestations of autoimmune diseases, indicates that IFI16 may be 
involved in the early steps of inflammation by modulating endothelial and 
keratinocyte cell function. To verify whether the induction of autoimmunity against 
IFI16 could indeed involve the redistribution of this nuclear protein in keratinocytes 
following an apoptotic stimulus like UVB, an in vitro model was developed in the 
laboratory of the applicant consisting of keratinocyte monolayers and human skin 
explants to investigate the fate of IFI16 following their irradiation with UVB [2]. In 
parallel, IFI16 expression and localization were analyzed in diseased skin sections 
from SLE patients. The results obtained clearly demonstrated that IFI16, normally 
restricted in the nucleus, could be induced to appear in the cytoplasm under 
conditions of UVB-induced cell injury. This nucleus to cytoplasm translocation was 
also observed in skin explants exposed to UVB and in the skin lesions from SLE 
patients not exposed to UVB irradiation. In addition, IFI16 was found in the 




Figure 10. IFI16 redistribution in ultraviolet (UV) B-irradiated human skin ex 
vivo. After 24 h in culture medium, explants were UVB irradiated at 1000 J m-2 
then harvested at 24 h (a) and 48 h (b) post-UVB treatment and processed for 
haematoxylin and eosin staining (H ⁄E) and immunohistochemical staining of 
IFI16 (blue); no counterstaining method was used. Arrows indicate pyknotic 
nuclei and hypereosinophilic cytoplasm (sunburn cells). Representative images 






In conclusion, we hypothesize that IFI16 overexpression and its subsequent 
extranuclear appearance during the process of cell death contribute to the 
pathogenic mechanism through the following steps: i) induction of inflammatory 
Figure 11. Localization of IFI16 in 
systemic lupus erythematosus 
(SLE) skin lesions. Sections of two 
representative SLE skin lesions 
stained with anti-IFI16 antibodies 
and visualized with SG substrate 
(blue; Vector Labs, Burlingame, CA, 
U.S.A.) are shown in panels (b) and 
(c). Normal skin processed in the 
same way is shown in panel (a) [2]. 
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response in the target cells; ii) release into the extracellular milieu and induction of 
specific autoimmunity; and iii) triggering of proinflammatory activity via the release 
of extracellular free IFI16 protein. 
2.5 IFI16 AS VIRAL RESTRICTION FACTOR FOR HCMV REPLICATION 
IFI16 has been shown to bind to and function as a pattern recognition receptor 
(PRR) of virus-derived intracellular DNA, and trigger the expression of antiviral 
cytokines via the STING-TBK1-IRF3 signaling pathway [43, 47, 50-59]. Although 
many different functions have been ascribed to IFI16 (and to other proteins of the 
PYHIN family), its role as an antiviral restriction factor has not yet been fully 
described. Recent studies implicate the involvement of IFI16 in host defense 
against HCMV [60]. The evidence supporting such a role of IFI16 is as follows: (i) 










embryonic lung fibroblasts (HELF) significantly increases HCMV replication 
efficiency as a result of augmented viral DNA synthesis; (ii) similarly, viral plaque 
formation is enhanced in the presence of an exogenous dominant-negative IFI16 
mutant that competes with the endogenous IFI16; (iii) overexpression of functional 
IFI16 in HCMV-infected HELFs decreases both virus yield and viral DNA copy 
number; and (iv) early and late, but not immediate-early viral mRNAs and proteins 
are strongly down-regulated under these same conditions, suggesting that IFI16 
exerts its main antiviral effect at the level of viral genome synthesis. This unique 
defense mechanism distinguishes the activity of IFI16 from that described for ND10.  
In more general terms, human viruses have to face powerful RF responses and 
thus have evolved a number of strategies to overcome RF attack. Viral antagonists 
can act through highly specialized mechanisms, such as coupling RFs to protein 
degradation pathways, causing their relocalization and thus down-regulating their 
functionality, or even by mimicking RF substrates [61]. In the case of HCMV, viral 
regulatory proteins (such as IE1p72, pp71, and others) mediate an efficient evasion 
from the antiviral state instituted by ND10, either by means of proteasomal 
degradation or by disrupting the host’s subnuclear structure [62, 63]. 
In this study (second author manuscript attached), we investigated the 
mechanisms used by HCMV to evade IFI16 restriction activity. We observed that 
starting from 72-96 hours post-infection (hpi), nuclear levels of IFI16 protein 
started to decrease in the nucleus and gradually increased in the cytoplasm of 
infected cells where it relocalized to the virus assembly complex (AC), as shown by 
its co-localization with the viral structural proteins gB and pp65. Finally, through 
the use of immunogold electron microscopy and co-precipitation experiments, we 
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provide evidence indicating that IFI16 eventually transits into the maturing virions 
embedded in the outer tegument layer. In conclusion, these data suggest that in 
order to overcome the restriction activity of IFI16, HCMV may stimulate its 
subcellular relocalization from the nucleus to the viral AC, followed by its inclusion 
















3 AIMS OF THE RESEARCH 
Collectively, present data and other findings suggest the following disease model: 
1) IFI16 expression is enhanced in lesional tissues as a result of abnormal type I IFN 
production (either endogenously produced or exogenously administered) and/or 
other proinflammatory stimuli, including UVB; 2) IFI16 expression triggers 
proinflammatory activation of endothelial cells and keratinocytes; 3) sustained 
IFI16 overexpression impairs cell growth and viability; 4) IFI16 is then released as a 
consequence of increased cell death by apoptosis/necrosis; 5) the released IFI16 
protein leads to a breakdown in tolerance to self-antigens and the injury of target 
cells (endothelial cells and keratinocytes); 6) circulating levels of free IFI16 directly 
damage endothelia (via the suppression of capillary formation), skin epithelia (via 
the suppression of stratified epithelium formation), and glandular epithelia (via the 
impairment of glandular physiology), thus amplifying the inflammatory process 
through local tissue destruction; 7) this loss of tolerance favors the generation of 
specific anti-IFI16 autoantibodies that may, paradoxically, exert protective activity 
by inhibiting the extracellular protein from binding to its specific receptors. 
To prove this disease model, the proposed research project will be developed as 
follows: 
Aim 1: In vivo studies to analyze the presence of IFI16 in the sera of systemic 
autoimmune patients and co-relate its occurrence with disease condition and other 
types of non-autoimmune diseases like non-SLE glomerulonephritis. 
Aim 2: In vitro studies aimed at elucidating the molecular actions of extracellular 
IFI16 on different primary endothelial cell lines. These studies will be grouped into: 
i) definition of the mechanisms by which extracellular IFI16, released upon cell 
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death, interacts with target cells (endothelial and epithelial cells), and ii) the 
clarification of the IFI16 receptor-stimulated molecular pathways that lead to cell 
damage and death. The outcome of these experiments will help us to understand 
the pathogenesis of the vasculopathy and the skin lesions that accompany 
















4 MATERIALS AND METHODS 
4.1 CELL CULTURES 
Primary human umbilical vein endothelial cells (HUVECs), pooled from multiple 
donors, cryopreserved at the end of the primary culture [64], were grown on 0.2% 
gelatin (Sigma-Aldrich, Milan, Italy) coated base in the presence of endothelial 
growth medium (EGM-2, Lonza-Milan) containing 2% fetal bovine serum, human 
recombinant vascular endothelial growth factor (rVEGF), basic fibroblast growth 
factor, human epidermal growth factor, IGF-1, hydrocortisone, ascorbic acid, 
heparin, gentamycin, amphotericin B including 1% Penicillin-Streptomycin solution 
(Sigma-Aldrich, Milan, Italy) which we describe as complete EGM-2. Low passage 
human dermal fibroblasts, HDF (ATCC), mouse fibroblasts, 3T3 (ATCC), HeLa (ATCC) 
and HaCaT (ATCC) cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) (Sigma-Aldrich, Milan, Italy) supplemented with 10% fetal bovine serum 
and 2% Penicillin-Streptomycin solution Unless specified, all cells were grown at 
37°C and 5% CO2. 
4.2 RECOMBINANT PROTEINS 
The entire coding sequence of the b isoform of human IFI16 was subcloned 
into the pET30a expression vector (Novagen, Madison, WI) containing an N-
terminal histidine tag. Protein Expression and affinity purification, followed by fast 
protein liquid chromatography (FPLC), were performed according to standard 
procedures. The purity of the proteins was assessed by 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. The FPLC purified protein was then 
processed with Toxin Eraser™ Endotoxin Removal Kit (Genscript, USA), while the 
LPS concentration of the processed product was measured using Toxin Sensor™ 
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Chromogenic LAL Endotoxin Assay Kit which was as low as 0.005 EU/ml. the final 
purified rIFI16 was stored at -80°C in endotoxin free vials. As negative controls in 
enzyme-linked immunosorbent assays (ELISA), the polypeptide encoded by the 
pET30a empty vector (control peptide) was expressed and purified according to the 
same protocol. 
4.3 PATIENTS AND DETERMINATION OF HUMAN EXTRACELLULAR IFI16 BY CAPTURE ELISA 
The study groups comprised patients suffering from Systemic Sclerosis, (n = 
50), Systemic Lupus Erythematosus, (n = 100), Sjogren Syndrome, (n = 49), 
Rheumatoid Arthritis (n = 50) and Non-SLE Glomerulonephritis (n = 46). As controls, 
we investigated sera from 116 sex- and age-matched healthy subjects. Written 
informed consent was obtained from all subjects according to the Declaration of 
Helsinki and approval was obtained from local ethics committees of corresponding 
hospital. 
For the determination of circulating extracellular IFI16, a capture ELISA was 
employed. Briefly, polystyrene micro-well plates (Nunc-Immuno MaxiSorp; Nunc, 
Roskilde, Denmark) were coated with a home-made polyclonal rabbit-anti-IFI16 
antibody (478-729 aa). Subsequently, plates were washed and free binding sites 
then saturated with PBS / 0.05% Tween / 3% BSA. After blocking, sera were added 
to plates in duplicate. Purified 6His-IFI16 protein was used as the standard and BSA 
served as the negative control. The samples were washed, monoclonal mouse anti-
IFI16 antibody (Santa Cruz, sc-8023) added, and then incubated for 1h at room 
temperature. After washing, horseradish peroxidase-conjugated anti-mouse 
antibody (GE Healthcare Europe GmbH, Milan, Italy) was added. Following the 
addition of the substrate (TMB; KPL, Gaithersburg, MD, USA), absorbance was 
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measured at 450nm using a microplate reader (TECAN, Mannedorf, Switzerland). 
Concentrations of extracellular IFI16 were determined using a standard curve for 
which increasing concentrations of purified 6His-IFI16 were used. 
4.4 CELL VIABILITY ASSAY 
Cells were seeded at a density of 1×104/well in a 96-well culture plate. After 
24 hours, cells were treated with different doses (10, 25 or 50µg/ml) of 
recombinant IFI16 protein (IFI16), mock-treated using the same volume of vehicle 
as each IFI16 dose (Mock), or left untreated (NT). Where indicated, different doses 
(1.75µgr or 3.5µgr) of antibody against IFI16 were added. Forty-eight hours after 
treatment, cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, Milan, Italy) method, as 
previously described [65]. 
4.5 TUBE MORPHOGENESIS ASSAY 
HUVEC were seeded in complete medium in 60-mm culture dishes coated 
with 0.2% gelatin (Sigma-Aldrich, Milan, Italy) and were treated for 48h with 
different doses (10 or 25µg/ml) of recombinant IFI16 protein (IFI16). As negative 
controls, cells were treated with the same volumes of vehicle (Mock) used for each 
IFI16 dose or left untreated (NT). Where indicated, different doses (1.75µgr or 
3.5µgr) of antibody against IFI16 were added. Tube morphogenesis assay was 
performed as described in [66]. Briefly, a 24-microwell plate, pre-chilled at -20°C, 
was coated with 250µl/well of Matrigel Basement Membrane (5mg/ml; Becton and 
Dickinson, Milan, Italy) and then incubated at 37°C for 30 min until solidified. 
HUVEC (8 x 104 cells/500µl per well) were seeded onto the matrix and allowed to 
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incubate at 37°C in 5% CO2. Plates were photographed after 6h using a Leica 
inverted microscope.  
4.6 MIGRATION ASSAY 
Twenty-four well transwell inserts with an 8µm pore size (Corning B.V. Life 
Sciences, Amsterdam, The Netherlands) were coated with a thin layer of gelatin 
(0.2%). HUVECs cultured in EGM-2 with 2% FBS and pre-treated with different 
concentrations of IFI16 recombinant protein or mock- or untreated for 48 hours 
were washed twice with PBS, trypsinized and plated into the upper chambers 
(4×105 cells) resuspended in 200µl of EBM-2 (Lonza, Italy), 0.1% BSA (Sigma-Aldrich, 
Milan, Italy) plus IFI16 recombinant protein or mock solution (the same amounts 
as in the 48h pre-treatment). The lower chambers were filled with 600µl EGM2 
containing VEGF and bFGF (as chemo-attractants) (Sigma-Aldrich, Milan, Italy), 2% 
FBS, and IFI16 recombinant protein or mock solution (the same amounts as in the 
upper chamber). The chambers were incubated for 5h at 37°C in a humidified 
atmosphere containing 5% CO2. After incubation, cells on the upper side of the 
filter were removed. The cells that had migrated to the lower side of the filter were 
washed twice with PBS, fixed with 2.5% glutaraldehyde (Sigma-Aldrich, Milan, Italy) 
for 20 min at room temperature, and stained with 0.5ml crystal violet (0.1% in 20% 
methyl alcohol solution) (Sigma-Aldrich, Milan, Italy). After washes, color was 
developed in 10% acetic acid and read in duplicate at 540nm on a microplate reader 
(Victor 3; Perkin-Elmer, Boston, MA).  
4.7 RIFI16-FITC MEMBRANE BINDING AND CONFOCAL MICROSCOPY 
HUVEC were seeded in 24-well plate in the presence of glass cover-slip and 
were grown overnight in presence of 1 µg/ml tunicamycin (Sigma-Aldrich, Milan, 
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Italy) in EGM-2 medium with 2% FBS and antibiotics. The cells were washed twice 
with cold PBS and incubated with increasing concentrations (10nM, 20nM, 30nM) 
of FITC labeled rIFI16 (FluoReporter® FITC Protein Labeling Kit by Invitrogen) for 90 
minutes at 4°C. Later the cells were washed twice with cold PBS and were fixed 
using 2% para-formaldehyde solution for 4 minutes. The PBS wash was repeated 
thrice and the coverslips were mounted on glass slides using ProLong® Gold 
Antifade Reagent by Invitrogen. The slides were observed using Leica Confocal 
Microscope at 490nm excitation wavelength for FITC in one channel while trans-
illuminated light in the other. 
4.8 CO-CULTURING AND IMMUNOFLUORESCENCE 
Co-culturing was performed with HeLa cells and HUVEC, as described in 
Koristka S. et.al [67]. 105 HeLa cells were seeded in 24 well-plate coated with 0.2% 
Gelatin in the presence of glass cover-slip and grown over-night in DMEM with 10% 
FCS at 37°C, 5% CO2. The cells were washed, suspended in PBS and lethally 
irradiated with UV-B lamp (HD 9021; Delta Ohm S.r.l., Padova, Italy). The dosage of 
1000 Wm2 was counted using a UVB irradiance meter cosine corrector with 
spectral range of 280–319 nm (LP 9021 RAD; Delta Ohm). Followed by this, 5×104 
HUVEC were added in the same well, grown in EGM-2 with 2% FCS until ready. 
Immunofluorescence was performed after 24hr, 36hr and 48hr using a home-made 
anti-IFI16 polyclonal as primary antibody and Alexa488- anti-rabbit (GE Healthcare) 
as secondary antibody. The cells were then fixed with 2% para-formaldehyde 
(Sigma-Aldrich, Milan, Italy), permeabilized with 0.2% Triton X-100 (Sigma-Aldrich, 
Milan, Italy) and nuclear stained with 1µg/ml propidium iodide (Sigma-Aldrich, 
Milan, Italy). The coverslips were mounted on glass slides using ProLong® Gold 
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Antifade Reagent by Invitrogen and the cells were observed by Leica confocal 
microscope. 
4.9 RADIO-IODINATION OF RIFI16 AND BINDING ASSAYS 
Iodination Beads were purchased from Thermo Fischer Scientific Inc. (Rockford, 
IL, USA) and used according to manufacturer’s instructions. Briefly, two dry beads 
were washed with rIFI16 elution buffer (50mM HEPES pH 7.5; 1M NaCl) (Sigma-
Aldrich, Milan, Italy), soaked dry and was incubated for 5 minutes with the solution 
of carrier-free 2mCi Na125I (Perkin Elmer Italia, Milan, Italy) and diluted in elution 
buffer. Later 200µg of rIFI16 was added and incubated for 15 minutes. The labeling 
reaction was passed through Zeba Spin Desalting Columns (Thermo Fischer 
Scientific Inc.) to remove excess Na125I or unincorporated 125I from the iodinated 
protein. The concentration of the final radioiodinated [125I]-rIFI16 was calculated 
using the following formula, where ‘C’ is the cpm counted, ‘V’ is volume of solution 
counted in ml and ‘Y’ is the specific activity of the radioligand in cpm/fmol.  
Concentration of [125I]-rIFI16 in (pM) = [‘C’cpm / ‘Y’cpm/fmol] / ‘V’ml. 
Binding assay was performed as described in [68, 69], 105 cells/well were 
seeded and attached in a 24-well plate with. Once ready, the medium was removed 
and the cells were washed with PBS. Further they were re-suspended with 
increasing concentrations of [125I]-rIFI16 (1-32nM) within different wells in the 
presence of 200nM unlabeled rIFI16 for Non-Specific Binding. Separately, other 
wells were re-suspended with [125I]-rIFI16 (1-32nM) without any unlabeled rIFI16 
for total binding. The incubation was performed at 4°C for 90 minutes. Later, the 
cells were washed with PBS to remove any loosely bound ligand and were then 
suspended in warm 1% SDS (Sigma-Aldrich, Milan, Italy) for 5 minutes. The SDS 
lysate of the cells was then measured on Cobra II Series Auto-Gamma Counter. All 
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the experiments were carried out in triplicates and the data was analyzed using 
non-linear regression equations from GraphPad Prism with 95% confidence 
intervals. 
4.10 COMPETITION AND INHIBITION OF [125I]-RIFI16 BINDING 
For binding competition experiments, cells were seeded into 96-well plates 
at a density of 104 cells/well. The medium was removed and cells were washed with 
PBS. HUVEC were then incubated at 4°C for 90 minutes with unlabeled rIFI16 (10-
1000nM) in the presence of 10nM [125I]-rIFI16. Binding inhibition was carried out 
overnight by incubating 10nM [125I]-rIFI16 with varying concentrations (10-
1000nM) of anti-IFI16 polyclonal N-terminal (1-205 aa) or C-terminal (478-729 aa) 
antibodies at 4°C. This mixture was then added to 104 HUVEC and incubated for 90 
minutes at 4°C. The loosely bound ligand was removed by washing twice with PBS, 
and cells were then detached using warm 1% SDS and the levels of [125I]-rIFI16-
binding to HUVEC assessed using a Cobra II Series Auto-Gamma Counter. The data 
were analyzed using non-linear regression equations in GraphPad Prism under 95% 
confidence intervals. 
4.11 NF-ΚB IMMUNOFLUORESCENCE 
Immunofluorescence was performed after 0 hr, 24 hr and 48 hr of rIFI16 
treatment using 1:1000 Nf-κB p65 monoclonal antibody (F-6) sc-8008 (Santa Cruz 
Biotechnology, Inc., USA) as primary and 1:500 Alexa488-anti-mouse (GE 
Healthcare) as secondary antibody. Briefly, after treatment the cells were fixed 
with 2% paraformaldehyde (Sigma-Aldrich, Milan, Italy) for 20 min at 4°C, 
permeabilized with 0.5% Triton X-100 (Sigma-Aldrich, Italy) for 30 min at RT, 
incubated with primary antibody for 2 hr at 37°C in a moist chamber, incubated 
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with secondary antibody and nuclear stain 1:500 TO-PRO-3 (Life-Technologies, 
Italy) for 1 hr at RT. The glass cover slips were mounted using ProLong® Gold 
Antifade Reagent (Invitrogen, Italy) and observed under Leica DM-IRE2 Confocal 
Microscope.  
4.12 RIFI16 TREATMENT AND QUANTITATIVE REAL-TIME PCR 
In the first experiment, HUVEC were grown in 6-well plate with 
complete/incomplete EGM-2 and treated with 50 µg/ml concentration of endo-
free rIFI16 [70] and vehicle/mock for 24 hrs and gene expression levels of different 
pro-inflammatory cytokines as listed in the (Table 1) was assessed with quantitative 
real-time PCR. In another set of experiment, HUVEC were treated with 50 µg/ml 
rIFI16 within a time-course of 0 hr, 4 hr, 12 hr, 24 hr, 48 hr and 72 hr and activity of 
highly modulated genes from the first experiment was assessed. After rIFI16 
treatment, HUVEC were trypsinized and m-RNA was extracted using TRI Reagent® 
(Sigma-Aldrich, Italy) as described in manufacturer protocol. The resulting m-RNA 
was treated with DNase I Amplification Grade kit (Sigma-Aldrich, Italy) as instructed. 
Later, 1 µg of m-RNA was used as a template first strand c-DNA synthesis using 
ImProm-II™ Reverse Transcription System (Promega, Italy) and C1000 Thermal 
Cycler (Bio-Rad, Italy) with annealing temperature 25°C for 5 min, followed by 
extension at 42°C for up to one hour. The reverse transcriptase was heat 
inactivated at 70°C for 15 min, while the final c-DNA preparation was quantified 
and stored at 4°C for immediate use. A random m-RNA sample was kept as RT- 
(without reverse transcriptase) to assess the presence of contaminating genomic 
DNA in the preparation. The quantitative real-time PCR analyses were performed 
using CFX96 Real-Time PCR Detection System (Bio-Rad, Italy) with SsoAdvanced™ 
Universal SYBR® Green Supermix (Bio-Rad, Italy) and amplification conditions as 
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instructed in manufacturer protocol, upto 40 cycles of PCR. Primer sequences are 
summarized in Table 1. The Ct values for each gene were normalized to the Ct 
values for GAPDH using the Ct equation. The level of target RNA, normalized to the 
endogenous reference and relative to the mock treated and untreated cells, was 
calculated by the comparative Ct method using the 2-δδCt equation. 
Cytokines Forward Primer Reverse Primer 
IL-1α CCGTTTTGACGACGCACTTG TTTGGCCATCTTGACTTCTTTGC 
IL-1β ACGAATCTCCGACCACCACT CCATGGCCACAACAACTGAC 
IL-2 GTAACCTCAACTCCTGCCACAA TGTTTCAGTTCTGTGGCCTTCT 
IL-4 TGCTGCCTCCAAGAACACAAC GGTTCCTGTCGAGCCGTTTC 
IL-6 GACCCAACCACAAATGCCA GTCATGTCCTGCAGCCACTG 
IL-8 CTGGCCGTGGCTCTCTTG CCTTGGCAAAACTGCACCTT 
IL-10 GGCGCTGTCATCGATTTCTTC GTTTCTCAAGGGGCTGGGTC 
IL-12p35 GCTCCAGAAGGCCAGACAAA GGCCAGGCAACTCCCATTAG 
IL-12p40 GCCCAGAGCAAGATGTGTCA CACCATTTCTCCAGGGGCAT 
IL-17A AGACCTCATTGGTGTCACTGC CTCTCAGGGTCCTCATTGCG 
IL-18 TGCAGTCTACACAGCTTCGG TCCAGGTTTTCATCATCTTCAGCTA 
IL-33 CAAAGAAGTTTGCCCCATGT AAGGCAAAGCACTCCACAGT 
CCL2 CTCTGCCGCCCTTCTGTG TGCATCTGGCTGAGCGAG 
CCL3 AGCTGACTACTTTGAGACGAGCA CGGCTTCGCTTGGTTAGGA 
CCL4 CTGCTCTCCAGCGCTCTCA GTAAGAAAAGCAGCAGGCGG 
CCL5 GACACCACACCCTGCTGCT TACTCCTTGATGTGGGCACG 
CCL7 GCACTTCTGTGTCTGCTGCT CAGCCTCTGCTTAGGGATTTT 
CCL8 GCCCTCCAAGATGAAGGTTT TCACGTTAAAGCAGCAGGTG 
CCL20 TCCTGGCTGCTTTGATGTCA TCAAAGTTGCTTGCTGCTTCTG 
TLR1 CTGGTATCTCAGGATGGTGTGC TTGGAGTTCTTCTAAGGGTATGTTCC 
Table 1: List of SYBR Green RT-PCR primers for pro-inflammatory genes  
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TLR2 GGCCAGCAAATTACCTGTGTG AGGCGGACATCCTGAACCT 
TLR3 TCCCAAGCCTTCAACGACTG TGGTGAAGGAGAGCTATCCACA 
TLR4 CTGCAATGGATCAAGGACCA TTATCTGAAGGTGTTGCACATTCC 
TLR5 TCGAGCCCCTACAAGGGAA CACTGAGACTCTGCTATACAAGCTA 
TLR7 TTACCTGGATGGAAACCAGCTAC TCAAGGCTGAGAAGCTGTAAGCTA 
TLR8 GAGAGCCGAGACAAAAACGTTC TGTCGATGATGGCCAATCC 
TLR9 TGGTGTTGAAGGACAGTTCTCTC CACTCGGAGGTTTCCCAGC 
TLR10 GAAAGGTTCCCGCAGACTTG TGGAGTTGAAAAAGGAGGTTATAG 
ICAM1 GCACATTGGTTGGCTATCTTCT GCCCGAAGCGTTTACTTTGA 
VCAM1 TTCCTCAGATTGGTGACTCCG AAAACTCACAGGGCTCAGGGTCAG 
VEGF ATCTGCATGGTGATGTTGGA GGGCAGAATCATCACGAAGT 





TNF-alpha ATACTGACCCACGGCTCCA GTTCGAGAAGATGATCTGACTGCC 
TGF-beta1 CCCAGCATCTGCAAAGCTC GTCAATGTACAGCTGCCGCA 





4.13 TRANSIENT TRANSFECTION AND LUCIFERASE ASSAY 
The low passage (3-4) HUVECs were plated at approximately 2×105 cells per 
well in 6-well culture plates and incubated overnight for next day 80% confluence. 
Effectene Transfection Reagent (Qiagen, Italy) was optimized for 75% transfection 
efficiency, maintaining normal biological activity of HUVEC. Briefly, total 0.4 µg of 
plasmid DNA was diluted to 100 µl of EB buffer while the Enhancer and Effectene 
reagent was used as 4 µl and 5 µl respectively, by following the preparation 
conditions as directed by the manufacturer. Cells were incubated with the 
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transfection reagent diluted in serum/antibiotics free incomplete EGM-2 upto 
maximum 4 hr at 37°C with 5% CO2. Later cells were incubated overnight with 
incomplete EGM-2 including 2% FCS and antibiotics, following which rIFI16, 50 
µg/ml was added to the culture for next 48 hr before measurement of luciferase 
activity. For each transfection, the cells were co-transfected with 0.05 µg of pRL-TK 
(Promega) and either of 0.3 µg of pGL2-IL8-wild type, 0.3 µg of pGL2-IL8-ΔNf-κB, 
0.3 µg of pGL2-IL8-ΔAP1 luciferase reporter plasmid or 0.3 µg control vector 
(pmaxGFP™ Vector). All plasmids were purified using the Toxin Eraser™ Endotoxin 
Removal Kit (Genscript, USA). Protein extracts were prepared and luciferase activity 
was measured using the Dual-Luciferase® Reporter Assay System (Promega, Italy) 
at the Victor X4 Multilabel Plate Reader (Perkin Elmer, Italy). 
4.14  STATISTICAL ANALYSIS 
All statistical tests were performed using GraphPad Prism version 5.00 for 
Windows (GraphPad, La Jolla, CA, USA). Positivity cut-off values for anti-IFI16 
antibodies were calculated as the 95th percentile for the control population and the 
Kruskal-Wallis test was used to measure associations. To test the effects of 
recombinant IFI16 protein (rIFI16) on biological functions of primary endothelial 
cells one-way analysis of variance (ANOVA) with Bonferroni adjustment for 
multiple comparisons was used. Significant upregulation of m-RNA expression was 




5.1 SERUM LEVELS OF IFI16 PROTEIN ARE INCREASED IN PATIENTS WITH SYSTEMIC AUTOIMMUNE 
DISEASES 
Sera were harvested from patients suffering from systemic autoimmune 
diseases characterized by endothelial dysfunction, including SSc, SLE, SjS, and RA. 
IFI16 serum levels were quantified using an in-house sandwich ELISA and compared 
with age- and sex-matched healthy controls. All absorbance levels were in the 
range of assay linearity. With the cut-off value set to the 95th percentile of the 
control population (27ng/ml), mean IFI16 levels were significantly increased in 
patients with SSc, SLE, RA, and SjS compared to the control group (4.7ng/ml) (SSc: 
25.4ng/ml, p<0.001; SLE: 23.5ng/ml, p<0.001; RA: 222ng/ml, p<0.001; SjS: 
88.2ng/ml, p<0.001). Of note, the sera from RA patients displayed the highest levels 
of circulating free protein. IFI16 levels above the 95th percentile for control subjects 
were observed in 34% of SSc, 37% of SLE, 47% of SjS, and 56% of RA patients (Figure 
13). By contrast, IFI16 levels in non-SLE GN patients did not show any significant 
difference in comparison with healthy controls. Since the objective of this part of 
the study was limited to demonstrate the presence of circulating IFI16 in patients’ 
sera for justifying the rest of the in vitro studies, correlation with clinico-






Figure 13. IFI16 protein levels in patients’ and controls’ sera determined using 
an in-house capture ELISA. Each dot represents the concentration of IFI16 
protein (expressed in ng/ml on a linear scale) in each individual subject: patients 
suffering from Systemic Sclerosis (SSc, n=50), Systemic Lupus Erythematosus 
(SLE, n=100), Sjogren’s Syndrome (SjS, n= 49), Rheumatoid Arthritis (RA, n=50), 
and non-SLE glomerulonephritis (non-SLE GN n=46) were investigated together 
with healthy controls (CTRL, n=116). The horizontal bars represent the median 
values. Values over the dotted line indicate the percentage of subjects with IFI16 
protein levels above the cut-off value (27ng/ml) calculated as the 95th percentile 





5.2 EFFECTS OF EXTRACELLULAR IFI16 ON DIFFERENT FUNCTIONS OF PRIMARY ENDOTHELIAL CELLS  
Abnormalities in angiogenesis are frequently present in systemic 
autoimmune diseases and may lead to tissue damage and premature vascular 
disease [71]. To verify whether extracellular IFI16 was also involved in this 
pathogenic process, HUVEC were treated with increasing concentrations of 
recombinant IFI16 protein (rIFI16) (10, 25 or 50µg/ml), mock-treated with the same 
volumes of vehicle (Mock), or left untreated (NT) and then assessed for cell viability 
at 48 hours incubation time by MTT assay. As shown in Figure 14A, the addition of 
endotoxin-free rIFI16 protein did not reduce the amount of viable adherent cells 
when compared to mock or untreated cells at the concentration of 10 and 25µg/ml, 
respectively. At the highest concentration used (50µg/ml), a slight reduction in cell 
viability was observed, and consequently the following studies were conducted 
with the lower doses. 
Next, to test whether the addition of rIFI16 to culture media altered other 
biological parameters of endothelial cells, HUVEC were treated as described for the 
assessment of cell viability (MTT assay) and then analyzed for their tubule 
morphogenesis and chemotactic activities. As shown in Figure 10B, exogenous 
administration of 25µg/ml rIFI16 severely limited tubulogenesis, with most cells 
generating incomplete tubules or aggregating into clumps. The extent of 
angiogenesis was quantified by counting the intact capillary-like tubules called as 
Lumens, which showed 75% decrease in its numerical value, as well as the number 
of interconnecting branch points showing 77% decrease. (Figure 14B). These 
effects were less pronounced when a lower dose of 10µg/ml rIFI16 was used with 
22% and 15% decrease respectively. In contrast, untreated or mock-treated HUVEC 
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plated onto matrigel supported the formation of an extensive interconnecting 
polygonal capillary-like network. 
Next, we evaluated the effects of rIFI16 on the migration phase of 
angiogenesis in a transwell migration assay routinely used to study cell migration 
in response to specific stimuli. HUVECs untreated, mock-treated, or incubated with 
rIFI16 (10 or 25µg/ml) for 48h were transferred into transwell migration chambers. 
As shown in Fig. 10C, only a small population of HUVECs cultured in the presence 
of 25µg/ml rIFI16 were able to migrate through the chamber (30% of migration), 
whereas mock-treatment resulted in considerable migration (95% and 87% for 
10µg/ml and 25µg/ml, respectively).  
Taken together, these results demonstrate the capability of extracellular 
rIFI16 to impair physiological functions of endothelial cells, such as the 
differentiation phases responsible for tube morphogenesis and migration.  
Figure 14. Extracellular IFI16 affects various biological functions of primary 
endothelial cells. HUVEC were treated with different doses of recombinant IFI16 
protein (rIFI16), the same volumes of vehicle (Mock), or left untreated (NT) for 
48h. (A) Viability analysis (MTT assay); the viability of control preparations (NT) 
was set to 100%. (B) Capillary-like tube formation assay (Matrigel). For a 
quantitative assessment of angiogenesis, the number of lumens and branch 
points was assessed (upper panels); representative images of three 
independent experiments are reported (lower panels). (C) Migration analysis 
(Transwell assay) results are reported as the percentage of migrated cells vs. 
untreated HUVECs. Values represent the mean±SD of 3 independent 
experiments, (**p<0.01, ***p<0.001; one-way ANOVA followed by Bonferroni's 









5.3 ANTI-N-TERMINUS IFI16 ANTIBODIES NEUTRALIZE THE CYTOTOXIC ACTIVITY OF IFI16 
To demonstrate that the effects exerted by IFI16 protein on target cells were 
specific and not a consequence of cell cytotoxicity, HUVEC were treated with 
25µg/ml rIFI16 in the presence or absence of specific rabbit polyclonal antibodies 
recognizing the N-terminal or the C-terminal domain of IFI16 protein. HUVEC 
incubated with rIFI16 in the presence of normal rabbit IgG were used as the positive 
control. As described in the previous section, rIFI16 severely affected the capability 
of endothelial cells to generate microtubules as well as their transwell migration 
activity, while the same effects were observed in presence of normal rabbit IgG 
(Figure 15A and 15B). In contrast, the presence of anti-N-terminus antibodies 
reduced the Lumens by 16%, Branch Points by 5% and migration by 1% while anti-
C-terminus antibodies reduced the Lumens by 60%, Branch Points by 32% and 
migration by 49%. This indicates the role of anti-N-terminus antibody in inhibiting 
the activities of IFI16 toward endothelial cells, restoring the tube formation and 
migratory activities. Altogether, these results suggest that the IFI16 activity is 
specific and that the functional domain resides at the N-terminus, where the PYD 



















Figure 15. Anti-IFI16 antibodies restore the biological activities of extracellular 
IFI16. HUVEC were treated for 48h with different doses of recombinant IFI16 
protein (rIFI16), the same volumes of vehicle (Mock), or left untreated (NT), 
alone or in combination with antibodies against IFI16. (A) Capillary-like tube 
formation assay (Matrigel). For a quantitative assessment of angiogenesis, the 
number of lumens and branch points was assessed (upper panels); 
representative images of three independent experiments are reported (lower 
panels). (B) Migration analysis (Transwell assay) results are reported as the 
percentage of migrated cells vs. untreated HUVECs. Values represent the 
mean±SD of 3 independent experiments (**p<0.01, ***p<0.001, one-way 




5.4 BINDING OF EXTRACELLULAR IFI16 ON THE PLASMA MEMBRANE OF HUVEC 
The finding that extracellular IFI16 impairs endothelial cell functions, 
including tube morphogenesis and transwell migration indicates a possible alarmin 
function as recently demonstrated for Danger and Pathogen-associated molecular 
pattern molecules collectively called as DAMPs, PAMPs such as autoantigen HMGB-
1 [72, 73].  Thus to find evidence in this direction it was important to evaluate the 
binding interaction of IFI16 on the plasma membrane of HUVEC. A series of binding 
experiments were conducted to verify the presence of high-affinity binding sites in 
the membranes of the target cells. In the previous section, it has been described 
that 25 µg/ml (300 nM) rIFI16 concentration is non-toxic to HUVEC, while they can 
still perform biological functions. Thus HUVEC were incubated with lowest 
concentrations (10nM, 20nM, and 30nM) of FITC-labeled rIFI16 to avoid toxicity or 
apoptosis and the binding was visualized by confocal microscopy. As shown in 
Figure 16A, binding of FITC-labeled rIFI16 was detected at least concentration of 
10nM, increased at 20nM, and saturated at 30nM. To avoid the non-specific 
binding of rIFI16 with sugar residues on plasma membrane, HUVEC were grown in 
presence of tunicamycin which inhibits N-glycosylation of proteins.  By contrast to 
above findings, human fibroblasts were negative for FITC-labeled rIFI16 at all the 
rIFI16 concentrations investigated (data not shown). 
Furthermore, to demonstrate that the binding of rIFI16 is of physiological 
relevance, co-culturing experiments were organized in such a way that UV-B 
irradiated cells release endogenous IFI16 [2] which in turn binds to neighboring 
HUVEC in the same system. As shown in Figure 16B, after 24 h HUVEC were 
observed to be surface bound with endogenous IFI16 released from HeLa cells, 
while by 36 h this bound IFI16 entered the cytoplasm and by 48 h it almost 
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disappeared. When fibroblasts were used instead of HUVEC, the binding was not 
observed, while also when HUVEC were cultured with normal HeLa cells, surface 
presence of IFI16 was not detected (data not shown). 
Figure 16. Plasma membrane binding of IFI16 to HUVEC. (A) Cells were left 
untreated (a, negative control) or incubated with increasing concentrations of 
FITC-labeled recombinant IFI16 (b, 10nM rIFI16-FITC; c, 20nM rIFI16-FITC; d, 
30nM rIFI16-FITC). Binding was detected by confocal microscopy using an 
excitation wavelength of 490nm for FITC in one channel and trans-illuminated 
light in the other. Representative images of three independent experiments are 
shown. (B) Endogenous IFI16 released by irradiated HeLa cells binds neighboring 
HUVEC. UV-B irradiated HeLa cells were co-cultured with HUVEC and after 24h, 
36h and 48h, dead cell debris were removed and immunofluorescence was 
performed on the remaining live HUVEC using a home-made anti-IFI16 
polyclonal as primary antibody and Alexa-488- anti-rabbit as secondary 
antibody. The cells were then fixed, permeabilized, nuclear-stained using 
propidium iodide and analyzed by confocal microscopy. Fibroblasts were 
employed as negative control. Representative images of three independent 







5.5 KINETICS OF RIFI16 BINDING ON DIFFERENT CELL LINES  
To get some insights into the binding characteristics of IFI16 to different cell 
lines, binding kinetics experiments using radioiodinated rIFI16 were performed. 
Specific binding was calculated as the difference between total and non-specific 
binding. As shown in Figure 17A, the specific binding of [125I]-rIFI16 to its binding 
site on HUVEC is saturable and has a dissociation constant (Kd) equal to 2.7nM; 
71.55 to 83.84fmol of [125I]-rIFI16 was estimated to saturate the binding sites on 
105 HUVEC, thus the maximal number of binding sites (Bmax) could be estimated to 
be in the range of 250,000 to 450,000 binding sites/cell. Furthermore, the binding 
of [125I]-rIFI16 on HUVEC was displaced by 10- to 100-fold of unlabeled rIFI16, 
demonstrating its competitive nature (Figure 17B). The inhibition constant (Ki) was 
calculated to be 14.43nM and the half maximal inhibitory concentration (IC50) was 
67.88nM. Similar results were obtained for HeLa and HaCaT cell lines, which also 
indicated saturable and competitive nature towards rIFI16 binding. As a negative 
control, human dermal fibroblasts (HDF) and murine fibroblasts (3T3) were 
accessed for specific and competitive binding of [125I]-rIFI16 in parallel with HUVEC 
(Figure 17A and 17B). Both HDF and 3T3 were found to exhibit non-saturable rIFI16 
binding, indicating the lack of any specific IFI16 binding sites. Moreover, the binding 
of rIFI16 on these cells was non-competitive in nature (Figure 17B). Also as reported 




Figure 17. Binding Kinetics of [125I]-rIFI16 on HUVEC, HDF, and 3T3 cells. (A) 
Specific binding of [125I]-rIFI16 on the plasma membrane of HUVEC, HeLa, 
HACAT, HDF, and 3T3 cells. (B) Competitive binding of [125I]-rIFI16 on HUVEC, 
HeLa, HaCaT, HDF, and 3T3 cells.  (C) The binding affinity (Kd), total bound ligand 
(Bmax) and the estimated number of binding sites per cell for different cell lines. 
The experiment was carried out in triplicates and data was analyzed using non-
linear regression equations from GraphPad Prism with 95% confidence intervals. 
All the experiments have been repeated at least three times and one 




5.6 [125I]-RIFI16 BINDING INHIBITION BY ANTI-IFI16 POLYCLONAL ANTIBODIES 
To evaluate the binding properties of rIFI16 to its receptor with respect to 
epitope mapping, we performed a binding inhibition assay using radioiodinated 
rIFI16 in the presence of increasing concentrations of antibodies recognizing the 
IFI16 N-terminal domain. As depicted in Figure 18, a gradual decrease in the bound 
[125I]-rIFI16 was observed with increasing concentrations of antibody (from 10 to 
1000nM). Conversely, the anti-IFI16 antibody recognizing the C-terminal domain 
(478-729 aa) was not able to inhibit the binding of [125I]-rIFI16 to its receptor. 
Together with the results from the functional assays, these observations provide 
evidence indicating that the N-terminal region of rIFI16 is required for its binding 





Figure 18. Binding inhibition of [125I]-rIFI16 using anti-IFI16 polyclonal 
antibodies. Antibody inhibition curve of HUVEC using anti-rIFI16 N-terminal (1-
205 aa) polyclonal antibodies (dashed) and C-term polyclonal antibodies (dot-
dashed). Competitive binding of rIFI16 and [125I]-rIFI16 to HUVEC (plain) was 
used as the control condition. The experiment was carried out in triplicates and 
data was analyzed using non-linear regression equations from GraphPad Prism 
with 95% confidence intervals. All the experiments have been repeated at least 






5.7 TIME-DEPENDENT NUCLEAR TRANSLOCATION OF NF-ΚB IN RIFI16 TREATED HUVEC 
The activation of Nf-κB is an important event in the propagation of 
inflammation, since Nf-κB transcriptionally regulate the production of different 
pro-inflammatory cytokines. Since, rIFI16 treatment produced detrimental changes 
in the HUVEC, as demonstrated in, we tested the pro-inflammatory activity of 
endo-free rIFI16 by observing the nuclear translocation of p65 sub-unit of Nf-κB. 
Using a simple immunofluorescence assay we determine the time-dependent 
activity of p65 in the cytoplasm of HUVEC, after rIFI16 treatment. As shown in Fig. 
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19, the p65 sub-unit, without rIFI16 treatment was located abundantly in the 
cytoplasm of HUVEC, which after 24 hr treatment time-point starts to migrate 
inside the nucleus. By 48 hr, most of the cells were having complete p65 sub-unit 
translocated into the nucleus, confirming the activation of Nf-κB. The results were 






Figure 19. Time dependant Nf-κB nuclear translocation 
HUVEC (-VEGF) treated with rIFI16 (10 μg/ml) for 0hr, 24hr and 48hr. 
Immunofluorescence was performed using 1:1000 anti-p65 polyclonal antibody 














5.8 M-RNA EXPRESSION OF PRO-INFLAMMATORY CYTOKINES AFTER RIFI16 TREATMENT 
The presence of extracellular IFI16 in the sera of autoimmune patients is a 
highly significant discovery which lead to strengthen our understanding on the 
leakage of endogenous molecules during cell death/apoptosis. It was thus 
necessary to evaluate the molecular activity of IFI16 protein when present in free 
form outside the cells. We treated endothelial cells with 50 μg/ml rIFI16 protein to 
understand the inflammatory properties of this protein. A broad range of pro-
inflammatory cytokines upregulation was assessed 24 hr post rIFI16 treatment as 
shown in Fig. 20A. Normalized m-RNA expression levels were then compared with 
untreated controls and the results were statistically analyzed by paired t-test. The 
expression levels of IL-8, CCL2, CCL5, CCL20, TLR3, TLR4, TLR9, ICAM1, VCAM1 and 
TNF-α were significantly upregulated, 24 hr post rIFI16 treatment as shown in Fig. 
20B.  
We further checked the time dependent expression of these cytokines to check 
the activation patterns at 0 hr, 4 hr, 12 hr, 24 hr, 48 hr and 72 hr. The m-RNA profile 
reveals the inflammatory stimulation by rIFI16 which could represent an early 
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Figure 20A: m-RNA expression profile of pro-inflammatory cytokines, 24 hr 
post rIFI16 treatment 
HUVEC treated with 50 μg/ml of rIFI16 for 24 hr were lysed and m-RNA was 
extracted, followed by ImProm-II c-DNA synthesis. RT-PCR was performed 
using Bio-Rad CFX96 instrument, using Bio-Rad Universal SYBR green master 
mix and amplification protocol as described by the manufacturer. The 
normalized expression of genes was calculated by 2-δδct equation and significant 
gene expression was analyzed by paired t-test comparison. 
Figure 20B: Time-dependent m-RNA expression of IL-8, CCL2, CCL5, CCL20, 
TLR3, TLR4, TLR9, ICAM1, VCAM1, TNF-α 
HUVEC treated with 50 μg/ml of rIFI16 for 0 hr, 4 hr, 12 hr, 24 hr, 48 hr and 72 
hr were lysed and m-RNA was extracted, followed by ImProm-II c-DNA 
synthesis. RT-PCR was performed using Bio-Rad CFX96 instrument, using Bio-
Rad Universal SYBR green master mix and amplification protocol as described 
by the manufacturer. The normalized expression of genes was calculated by 2-
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In this study, we demonstrate for the first time: i) the presence of significant 
levels of extracellular IFI16 protein in the sera of patients affected by systemic 
autoimmune diseases, including SSc, SjS, SLE and RA but not in non-SLE GN as 
compared to healthy controls, ii) that the extracellular IFI16 exerts biological effects 
on endothelial cells upon binding to a specific cell surface receptor and iii) 
extracellular IFI16 acts as an inflammatory stimuli for the production of different 
cytokines which could be the first steps of an autoimmune syndrome. These 
findings have important implications as they provide novel insights into the role of 
IFI16 in the pathogenesis of systemic autoimmune diseases. Various research 
groups, including ours, have shown that following transfection of virus-derived 
DNA [74, 75], or treatment with UVB [2], IFI16 delocalizes from the nucleus to the 
cytoplasm and is then eventually released into the extracellular milieu. Consistent 
with these observations, we now demonstrate the presence of circulating IFI16 
protein in the sera of patients affected by systemic autoimmune diseases, but not 
in patients with non-autoimmune inflammatory diseases like non-SLE GN. Skin 
manifestations and vasculopathy are common components of a number of 
autoimmune diseases and represent a significant source of morbidity [76, 77]. Thus, 
to investigate the hypothesis that circulating IFI16 is able to exert harmful effects 
on target cells in vivo, an in vitro cell model consisting of primary endothelial cells 
(HUVEC) was used to test the activity of extracellular IFI16 on cell functions. These 
experiments clearly demonstrate that extracellular IFI16 affects some biological 
processes of endothelial cells, including tube morphogenesis and transwell 
migration. The specificity of these effects was assessed by the addition of anti-IFI16 
antibodies which were able to neutralize the activity of the protein blocking its 
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inhibitory effects. Subsequently, the presence of IFI16 in the extracellular 
environment could also be the main reason behind the presence of anti-IFI16 
autoantibodies in autoimmune patients’ sera [78]. Together, these observations 
suggest the possible role of IFI16 in the clinical manifestation of autoimmune 
diseases, due to its presence in the extracellular environment. Since IFI16 can be 
released extracellularly which further reflect distinct extracellular biological 
activities, it is an indication of a novel alarmin function of this interferon inducible 
protein. Such stress-dependent shuttling, release, binding to cell surface was 
described in the past for autoantigen La/SS-B [79] and recently reviewed for 
HMGB1 protein [73] which upon release, binds to the cell surface receptors of 
neighboring cells. Thus as part of alarmin function, we further hypothesized that 
once released IFI16 protein must also bind neighboring cells to communicate the 
stress signal. In this direction, we assessed the affinity of IFI16 towards the plasma 
membrane of HUVEC. Confocal images visualized patterned binding of FITC labeled 
rIFI16 protein on the plasma membrane, which gave us the first preliminary 
evidence of the existence of an IFI16 interacting molecule which we suspect to be 
receptor-kind. Furthermore, we found experimental evidence that endogenous 
IFI16 protein released by dying cells bind neighboring cells. As a consequence of 
this binding, time-lapse studies proved its further entry into the cytoplasm. 
Moreover, such binding and transport of IFI16 was observed in different cell lines 
with different affinities. The experiments using radiolabeled IFI16 to investigate the 
binding kinetics of IFI16 in the HUVEC provide strong evidence supporting the 
presence of specific binding sites in the plasma membrane through which IFI16 
exerts its cytotoxic activity. These binding sites were found to be saturable and 
competitive for IFI16, while the binding experiments in HUVEC indicate the 
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presence of approximately 250,000 to 450,000 binding sites per cell, with a 
dissociation constant (Kd) of 2.7nM. Similar binding characteristics were shown by 
different epithelial cell lines while a completely un-related cell line like fibroblasts 
demonstrated non-specific binding. This explains the specificity of IFI16 binding 
which is mostly restricted towards endothelium and epithelium. Neutralization 
experiments employing antibodies directed against different regions of the protein 
allowed us to demonstrate that the N-terminus, containing the PYD domain, is 
responsible for binding interaction. Consistent with this observation, the same 
antibodies were able to neutralize the biological activity of extracellular IFI16, as 
described earlier. 
The activity of IFI16 is more similar to the DAMPs, for example HMGB1, which 
is released during cell death/necrosis/injury in the extracellular milieu. HMGB1 
interacts with TLRs and RAGE to produce pro-inflammatory cytokines which further 
propagate the stress response and inflammation. We hypothesized the properties 
of IFI16 to be similar to such DAMPs. In relation to this hypothesis our quantitative 
PCR experiments demonstrate that IFI16 has cytokine stimulating activity which 
was proved by the overexpression of major chemokines such as IL-8, CCl2, CCL5 
and CCL20. On the other hand TLRs such as TLR2, TLR4 and TLR9 were also observed 
to be modulated by IFI16 treatment on endothelial cells. These results suggest the 
specificity of IFI16 action on endothelial cells and other components of immune 
machinery. There could be a possibility of interacting TLRs in IFI16 mediated 
cytokine production and for the same our future experiments will be addressed to 
unravel the molecular mechanisms underlying IFI16 cytokine stimulating activity. 
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Overall the activity of IFI16 can be summarized as shown in the Figure. 20, 








In summary, our results provide evidence for a novel alarmin function of 
IFI16 protein which is overexpressed upon inflammatory stimuli and then released 
in the extracellular environment. Once released, IFI16 binds to neighboring cells to 
Nf-κB dependent pathways for the production of different cytokines/chemokines 
which could propagate the stress signal causing damage. The presence of anti-IFI16 
autoantibodies have been detected in many autoimmune diseases [32, 80-82], thus 
the release of IFI16 in the extracellular milieu and its cytokine stimulating activity 
represent a DAMP like behavior. We thus pronounce IFI16 as a novel DAMP like 
molecule which could be responsible for chronic stimulation of the immune system 
which marks the first step for the development of autoimmunity. 
To shed some light into the viral restriction activity of IFI16 against HCMV, 
we recently demonstrated that the DNA sensor IFI16 restricts HCMV replication by 
down-regulating viral early and late but not immediate-early mRNAs and their 
protein expression [60]. In the attached manuscript (second author) we 
demonstrate that at an early time point during the in vitro infection of low-passage 
human embryonic lung fibroblasts (HELF), IFI16 binds to HCMV DNA. However, 
during a later phase following infection, IFI16 is mislocalized to the cytoplasmic 
virus assembly complex (AC), where it colocalizes with viral structural proteins. 
Indeed, upon its binding to pUL97, IFI16 undergoes phosphorylation and relocalizes 
to the cytoplasm of HCMV-infected cells. ESCRT (Endosomal Sorting Complex 
Required for Transport) machinery regulates the translocation of IFI16 into the 
virus AC by sorting and trafficking IFI16 into multivesicular bodies (MVB), as 
demonstrated by the interaction of IFI16 with two MVB markers: Vps4 and TGN46. 
Finally, IFI16 becomes incorporated into the newly assembled virions as 
demonstrated by Western blot analysis of purified virions and electron microscopy. 
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Together, these results suggest that HCMV has evolved mechanisms to mislocalize 
and hijack IFI16, trapping it within mature virions. However, the significance of this 




















1. Dowling, J.K. and L.A. O'Neill, Biochemical regulation of the inflammasome. 
Crit Rev Biochem Mol Biol, 2012. 47(5): p. 424-43. 
2. Costa, S., et al., Redistribution of the nuclear protein IFI16 into the cytoplasm 
of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen 
processing. Br J Dermatol, 2011. 164(2): p. 282-90. 
3. Gariglio, M., et al., Immunohistochemical expression analysis of the human 
interferon-inducible gene IFI16, a member of the HIN200 family, not 
restricted to hematopoietic cells. J Interferon Cytokine Res, 2002. 22(7): p. 
815-21. 
4. Ermann, J. and C.G. Fathman, Autoimmune diseases: genes, bugs and failed 
regulation. Nat Immunol, 2001. 2(9): p. 759-61. 
5. Paludan, S.R., et al., Recognition of herpesviruses by the innate immune 
system. Nat Rev Immunol, 2011. 11(2): p. 143-54. 
6. Sinha, A.A., M.T. Lopez, and H.O. McDevitt, Autoimmune diseases: the failure 
of self tolerance. Science, 1990. 248(4961): p. 1380-8. 
7. Jacobson, D.L., et al., Epidemiology and estimated population burden of 
selected autoimmune diseases in the United States. Clin Immunol 
Immunopathol, 1997. 84(3): p. 223-43. 
8. Kong, J.S., S.S. Teuber, and M.E. Gershwin, Potential adverse events with 
biologic response modifiers. Autoimmun Rev, 2006. 5(7): p. 471-85. 
9. Borden, E.C., et al., Interferons at age 50: past, current and future impact on 
biomedicine. Nat Rev Drug Discov, 2007. 6(12): p. 975-90. 
10. Gualtierotti, R., et al., Updating on the pathogenesis of systemic lupus 
erythematosus. Autoimmun Rev, 2010. 10(1): p. 3-7. 
 
80 
11. Waldman, M. and M.P. Madaio, Pathogenic autoantibodies in lupus nephritis. 
Lupus, 2005. 14(1): p. 19-24. 
12. Mok, C.C., Biomarkers for lupus nephritis: a critical appraisal. J Biomed 
Biotechnol, 2010. 2010: p. 638413. 
13. Hoffmann, M.H., et al., Nucleic acid-associated autoantigens: pathogenic 
involvement and therapeutic potential. J Autoimmun, 2010. 34(3): p. J178-
206. 
14. Gu, Y.S., et al., The immunobiology of systemic sclerosis. Semin Arthritis 
Rheum, 2008. 38(2): p. 132-60. 
15. Abraham, D.J. and J. Varga, Scleroderma: from cell and molecular 
mechanisms to disease models. Trends Immunol, 2005. 26(11): p. 587-95. 
16. Tan, F.K., Autoantibodies against PDGF receptor in scleroderma. N Engl J Med, 
2006. 354(25): p. 2709-11. 
17. Coelho, F.M., et al., The chemokine receptors CXCR1/CXCR2 modulate 
antigen-induced arthritis by regulating adhesion of neutrophils to the 
synovial microvasculature. Arthritis Rheum, 2008. 58(8): p. 2329-37. 
18. Dieude, P., Rheumatic diseases: environment and genetics. Joint Bone Spine, 
2009. 76(6): p. 602-7. 
19. Dieguez-Gonzalez, R., et al., Association of interferon regulatory factor 5 
haplotypes, similar to that found in systemic lupus erythematosus, in a large 
subgroup of patients with rheumatoid arthritis. Arthritis Rheum, 2008. 58(5): 
p. 1264-74. 
20. Orozco, G., et al., Association of STAT4 with rheumatoid arthritis: a 
replication study in three European populations. Arthritis Rheum, 2008. 
58(7): p. 1974-80. 
 
81 
21. Zervou, M.I., et al., Association of a TRAF1 and a STAT4 gene polymorphism 
with increased risk for rheumatoid arthritis in a genetically homogeneous 
population. Hum Immunol, 2008. 69(9): p. 567-71. 
22. Banchereau, J., V. Pascual, and A.K. Palucka, Autoimmunity through cytokine-
induced dendritic cell activation. Immunity, 2004. 20(5): p. 539-50. 
23. Trinchieri, G. and A. Sher, Cooperation of Toll-like receptor signals in innate 
immune defence. Nat Rev Immunol, 2007. 7(3): p. 179-90. 
24. Biggioggero, M., L. Gabbriellini, and P.L. Meroni, Type I interferon therapy 
and its role in autoimmunity. Autoimmunity, 2010. 43(3): p. 248-54. 
25. Hall, J.C. and A. Rosen, Type I interferons: crucial participants in disease 
amplification in autoimmunity. Nat Rev Rheumatol, 2010. 6(1): p. 40-9. 
26. Obermoser, G. and V. Pascual, The interferon-alpha signature of systemic 
lupus erythematosus. Lupus, 2010. 19(9): p. 1012-9. 
27. Crow, M.K., Type I interferon and autoimmune disease. Autoimmunity, 2003. 
36(8): p. 445-6. 
28. Crow, M.K., Type I interferon in systemic lupus erythematosus. Curr Top 
Microbiol Immunol, 2007. 316: p. 359-86. 
29. Nordmark, G., G.V. Alm, and L. Ronnblom, Mechanisms of Disease: primary 
Sjogren's syndrome and the type I interferon system. Nat Clin Pract 
Rheumatol, 2006. 2(5): p. 262-9. 
30. Kimoto, O., et al., Activation of the interferon pathway in peripheral blood of 
patients with Sjogren's syndrome. J Rheumatol, 2011. 38(2): p. 310-6. 
31. Eloranta, M.L., et al., Type I interferon system activation and association with 




32. Mondini, M., et al., Role of the interferon-inducible gene IFI16 in the 
etiopathogenesis of systemic autoimmune disorders. Ann N Y Acad Sci, 2007. 
1110: p. 47-56. 
33. Gariglio, M., et al., The multifaceted interferon-inducible p200 family 
proteins: from cell biology to human pathology. J Interferon Cytokine Res, 
2011. 31(1): p. 159-72. 
34. Bertin, J. and P.S. DiStefano, The PYRIN domain: a novel motif found in 
apoptosis and inflammation proteins. Cell Death Differ, 2000. 7(12): p. 1273-
4. 
35. Park, H.H., et al., The death domain superfamily in intracellular signaling of 
apoptosis and inflammation. Annu Rev Immunol, 2007. 25: p. 561-86. 
36. Aglipay, J.A., et al., A member of the Pyrin family, IFI16, is a novel BRCA1-
associated protein involved in the p53-mediated apoptosis pathway. 
Oncogene, 2003. 22(55): p. 8931-8. 
37. Choubey, D., et al., Interferon-inducible p200-family proteins as novel sensors 
of cytoplasmic DNA: role in inflammation and autoimmunity. J Interferon 
Cytokine Res, 2010. 30(6): p. 371-80. 
38. Mondini, M., et al., The interferon-inducible HIN-200 gene family in apoptosis 
and inflammation: implication for autoimmunity. Autoimmunity, 2010. 
43(3): p. 226-31. 
39. Albrecht, M., D. Choubey, and T. Lengauer, The HIN domain of IFI-200 
proteins consists of two OB folds. Biochem Biophys Res Commun, 2005. 
327(3): p. 679-87. 
40. Yan, H., et al., RPA nucleic acid-binding properties of IFI16-HIN200. Biochim 
Biophys Acta, 2008. 1784(7-8): p. 1087-97. 
 
83 
41. Krieg, A.M., AIMing 2 defend against intracellular pathogens. Nat Immunol, 
2010. 11(5): p. 367-9. 
42. Krieg, A.M., AIMing 2 detect foreign DNA. Sci Signal, 2009. 2(77): p. pe39. 
43. Unterholzner, L., et al., IFI16 is an innate immune sensor for intracellular DNA. 
Nat Immunol, 2010. 11(11): p. 997-1004. 
44. Gugliesi, F., et al., Up-regulation of the interferon-inducible IFI16 gene by 
oxidative stress triggers p53 transcriptional activity in endothelial cells. J 
Leukoc Biol, 2005. 77(5): p. 820-9. 
45. Caposio, P., et al., A novel role of the interferon-inducible protein IFI16 as 
inducer of proinflammatory molecules in endothelial cells. J Biol Chem, 2007. 
282(46): p. 33515-29. 
46. Hornung, V., et al., AIM2 recognizes cytosolic dsDNA and forms a caspase-1-
activating inflammasome with ASC. Nature, 2009. 458(7237): p. 514-8. 
47. Kerur, N., et al., IFI16 acts as a nuclear pathogen sensor to induce the 
inflammasome in response to Kaposi Sarcoma-associated herpesvirus 
infection. Cell Host Microbe, 2011. 9(5): p. 363-75. 
48. Bijl, M., et al., Inflammatory clearance of apoptotic cells after UVB challenge. 
Autoimmunity, 2007. 40(4): p. 244-8. 
49. Bijl, M. and C.G. Kallenberg, Ultraviolet light and cutaneous lupus. Lupus, 
2006. 15(11): p. 724-7. 
50. Ansari, M.A., et al., Constitutive interferon-inducible protein 16-
inflammasome activation during Epstein-Barr virus latency I, II, and III in B 
and epithelial cells. J Virol, 2013. 87(15): p. 8606-23. 
 
84 
51. Cristea, I.M., et al., Human cytomegalovirus pUL83 stimulates activity of the 
viral immediate-early promoter through its interaction with the cellular IFI16 
protein. J Virol, 2010. 84(15): p. 7803-14. 
52. Cristea, I.M., et al., Host factors associated with the Sindbis virus RNA-
dependent RNA polymerase: role for G3BP1 and G3BP2 in virus replication. J 
Virol, 2010. 84(13): p. 6720-32. 
53. Horan, K.A., et al., Proteasomal degradation of herpes simplex virus capsids 
in macrophages releases DNA to the cytosol for recognition by DNA sensors. 
J Immunol, 2013. 190(5): p. 2311-9. 
54. Johnson, K.E., L. Chikoti, and B. Chandran, Herpes simplex virus 1 infection 
induces activation and subsequent inhibition of the IFI16 and NLRP3 
inflammasomes. J Virol, 2013. 87(9): p. 5005-18. 
55. Orzalli, M.H., N.A. DeLuca, and D.M. Knipe, Nuclear IFI16 induction of IRF-3 
signaling during herpesviral infection and degradation of IFI16 by the viral 
ICP0 protein. Proc Natl Acad Sci U S A, 2012. 109(44): p. E3008-17. 
56. Singh, V.V., et al., Decreased pattern recognition receptor signaling, 
interferon-signature, and bactericidal/permeability-increasing protein gene 
expression in cord blood of term low birth weight human newborns. PLoS One, 
2013. 8(4): p. e62845. 
57. Li, T., J. Chen, and I.M. Cristea, Human cytomegalovirus tegument protein 
pUL83 inhibits IFI16-mediated DNA sensing for immune evasion. Cell Host 
Microbe, 2013. 14(5): p. 591-9. 
58. Berg, R.K., et al., T cells detect intracellular DNA but fail to induce type I IFN 
responses: implications for restriction of HIV replication. PLoS One, 2014. 
9(1): p. e84513. 
 
85 
59. Monroe, K.M., et al., IFI16 DNA sensor is required for death of lymphoid CD4 
T cells abortively infected with HIV. Science, 2014. 343(6169): p. 428-32. 
60. Gariano, G.R., et al., The intracellular DNA sensor IFI16 gene acts as 
restriction factor for human cytomegalovirus replication. PLoS Pathog, 2012. 
8(1): p. e1002498. 
61. Duggal, N.K. and M. Emerman, Evolutionary conflicts between viruses and 
restriction factors shape immunity. Nat Rev Immunol, 2012. 12(10): p. 687-
95. 
62. Tavalai, N. and T. Stamminger, Intrinsic cellular defense mechanisms 
targeting human cytomegalovirus. Virus Res, 2011. 157(2): p. 128-33. 
63. Saffert, R.T. and R.F. Kalejta, Inactivating a cellular intrinsic immune defense 
mediated by Daxx is the mechanism through which the human 
cytomegalovirus pp71 protein stimulates viral immediate-early gene 
expression. J Virol, 2006. 80(8): p. 3863-71. 
64. Baggetta, R., et al., The interferon-inducible gene IFI16 secretome of 
endothelial cells drives the early steps of the inflammatory response. Eur J 
Immunol, 2010. 40(8): p. 2182-9. 
65. Pauwels, R., et al., Rapid and automated tetrazolium-based colorimetric 
assay for the detection of anti-HIV compounds. J Virol Methods, 1988. 20(4): 
p. 309-21. 
66. Gugliesi, F., et al., Tumor-derived endothelial cells evade apoptotic activity of 
the interferon-inducible IFI16 gene. J Interferon Cytokine Res, 2011. 31(8): p. 
609-18. 
67. Koristka, S., et al., Retargeting of regulatory T cells to surface-inducible 
autoantigen La/SS-B. J Autoimmun, 2013. 42: p. 105-16. 
 
86 
68. Coleman, J.W. and R.C. Godfrey, The number and affinity of IgE receptors on 
dispersed human lung mast cells. Immunology, 1981. 44(4): p. 859-63. 
69. Imai, Y., et al., Epidermal growth factor receptors and effect of epidermal 
growth factor on growth of human breast cancer cells in long-term tissue 
culture. Cancer Res, 1982. 42(11): p. 4394-8. 
70. Gugliesi, F., et al., Nuclear DNA sensor IFI16 as circulating protein in 
autoimmune diseases is a signal of damage that impairs endothelial cells 
through high-affinity membrane binding. PLoS One, 2013. 8(5): p. e63045. 
71. Guiducci, S., et al., Mechanisms of vascular damage in SSc--implications for 
vascular treatment strategies. Rheumatology (Oxford), 2008. 47 Suppl 5: p. 
v18-20. 
72. Bianchi, M.E., DAMPs, PAMPs and alarmins: all we need to know about 
danger. J Leukoc Biol, 2007. 81(1): p. 1-5. 
73. Harris, H.E., U. Andersson, and D.S. Pisetsky, HMGB1: a multifunctional 
alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol, 
2012. 8(4): p. 195-202. 
74. Keating, S.E., M. Baran, and A.G. Bowie, Cytosolic DNA sensors regulating 
type I interferon induction. Trends Immunol, 2011. 32(12): p. 574-81. 
75. Unterholzner, L. and A.G. Bowie, Innate DNA sensing moves to the nucleus. 
Cell Host Microbe, 2011. 9(5): p. 351-3. 
76. Kaplan, M.J., Endothelial damage and autoimmune diseases. Autoimmunity, 
2009. 42(7): p. 561-2. 
77. Rashtak, S. and M.R. Pittelkow, Skin involvement in systemic autoimmune 
diseases. Curr Dir Autoimmun, 2008. 10: p. 344-58. 
 
87 
78. Caneparo, V., et al., Anti-IFI16 antibodies and their relation to disease 
characteristics in systemic lupus erythematosus. Lupus, 2013. 22(6): p. 607-
13. 
79. Bachmann, M., T. Zaubitzer, and W.E. Muller, The autoantigen La/SSB: 
detection on and uptake by mitotic cells. Exp Cell Res, 1992. 201(2): p. 387-
98. 
80. Rekvig, O.P., et al., Autoantibodies in lupus: culprits or passive bystanders? 
Autoimmun Rev, 2012. 11(8): p. 596-603. 
81. Mondini, M., et al., A novel autoantigen to differentiate limited cutaneous 
systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-
inducible gene IFI16. Arthritis Rheum, 2006. 54(12): p. 3939-44. 
82. Costa, S., et al., Detection of anti-IFI16 antibodies by ELISA: clinical and 
serological associations in systemic sclerosis. Rheumatology (Oxford), 2011. 












1. Gugliesi F*, Bawadekar M*, De Andrea M, Dell’Oste V, Caneparo V, Gariglio 
M and Landolfo S. Nuclear DNA Sensor IFI16 as Circulating Protein in 
Autoimmune Diseases Is a Signal of Damage that Impairs Endothelial Cells 
through High-Affinity Membrane Binding. PLoS ONE, 2013, 8(5): e63045. 
doi:10.1371/journal.pone.0063045. (* Contributed Equally) 
 
2. Dell’Oste V, Gatti D, Gugliesi F, De Andrea M, Bawadekar M, Lo Cigno I, 
Biolatti M, Vallino M, Marschall M, Gariglio M and Landolfo S. Early stage 
IFI16 cytoplasmic translocation and late stage entrapment into egressing 
virions during HCMV infection. (submitted) 
Nuclear DNA Sensor IFI16 as Circulating Protein in
Autoimmune Diseases Is a Signal of Damage that Impairs
Endothelial Cells through High-Affinity Membrane
Binding
Francesca Gugliesi1., Mandar Bawadekar2,3., Marco De Andrea1,2, Valentina Dell’Oste1,
Valeria Caneparo2,3, Angela Tincani4, Marisa Gariglio2,3, Santo Landolfo1*
1 Department of Public Health and Pediatric Sciences, University of Turin, Medical School, Turin, Italy, 2 Department of Translational Medicine, University of Piemonte
Orientale ‘‘Amedeo Avogadro’’, Medical School, Novara, Italy, 3 Interdisciplinary Research Center of Autoimmune Diseases, Department of Translational Medicine,
University of Piemonte Orientale ‘‘Amedeo Avogadro’’, Medical School, Novara, Italy, 4 Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia,
Brescia, Italy
Abstract
IFI16, a nuclear pathogenic DNA sensor induced by several pro-inflammatory cytokines, is a multifaceted protein with
various functions. It is also a target for autoantibodies as specific antibodies have been demonstrated in the sera of patients
affected by systemic autoimmune diseases. Following transfection of virus-derived DNA, or treatment with UVB, IFI16
delocalizes from the nucleus to the cytoplasm and is then eventually released into the extracellular milieu. In this study,
using an in-house capture enzyme-linked immunsorbent assay we demonstrate that significant levels of IFI16 protein can
also exist as circulating form in the sera of autoimmune patients. We also show that the rIFI16 protein, when added in-vitro
to endothelial cells, does not affect cell viability, but severely limits their tubulogenesis and transwell migration activities.
These inhibitory effects are fully reversed in the presence of anti-IFI16 N-terminal antibodies, indicating that its extracellular
activity resides within the N-terminus. It was further demonstrated that endogenous IFI16 released by apoptotic cells bind
neighboring cells in a co-culture. Immunofluorescence assays revealed existence of high-affinity binding sites on the plasma
membrane of endothelial cells. Free recombinant IFI16 binds these sites on HUVEC with dissociation constant of 2.7 nM,
radioiodinated and unlabeled IFI16 compete for binding sites, with inhibition constant (Ki) of 14.43 nM and half maximal
inhibitory concentration (IC50) of 67.88 nM; these data allow us to estimate the presence of 250,000 to 450,000 specific
binding sites per cell. Corroborating the results from functional assays, this binding could be completely inhibited using
anti-IFI16 N-terminal antibody, but not with an antibody raised against the IFI16 C-terminal. Altogether, these data
demonstrate that IFI16 may exist as circulating protein in the sera of autoimmune patients which binds endothelial cells
causing damage, suggesting a new pathogenic and alarmin function through which this protein triggers the development
of autoimmunity.
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Introduction
A wealth of data now exists demonstrating the critical role of
interferons (IFNs) in the pathogenesis and perpetuation of
autoimmunity [1–5]. Genomic studies have revealed that type I
IFN inducible genes are markedly overexpressed in the peripheral
blood of patients with systemic autoimmune diseases including
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc),
and Sjogren’s Syndrome (SjS) [6–8]. In SLE patients, this so-called
‘‘IFN signature’’ is generally associated with active disease states,
renal, and CNS involvement [9]. Together, these findings have led
to the hypothesis that type I IFNs (IFN-a and IFN-b) may be the
master cytokines responsible for the initiation and progression of
the autoimmune process [10–12].
One family of IFN-inducible genes is the HIN200/Ifi200 gene
family, which encodes evolutionary related human (IFI16, IFIX,
MNDA, and AIM2) and murine (Ifi202a, Ifi202b, Ifi203, Ifi204,
Ifi205/D3, and Ifi206) proteins. The common domain architec-
ture of this protein family consists of one or two copies of the HIN
domain (a 200 amino acid repeat) and an N-terminal PYD
domain, also named PAAD, DAPIN, or Pyrin. The PYD domain,
commonly found in death-family proteins, like Pyrin and ASC, is
present in the N terminus of most HIN200 proteins, suggesting a
role of these proteins in inflammation and apoptosis [13,14]. The
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IFI16 protein is specifically expressed in vascular endothelial cells,
keratinocytes, and hematopoietic cells [15] and has been recently
shown to act as a foreign DNA sensor [16–19]. We have
previously demonstrated that oxidative stress and various proin-
flammatory cytokines can also trigger IFI16 nuclear expression
[20] and [21]. In addition, a role of IFI16 as an inducer of
proinflammatory molecules (e.g. ICAM-1, RANTES, and CCL20)
and apoptosis in endothelial cells has also been observed,
supporting its role in the initial steps of the inflammatory processes
that precede the onset of autoimmune syndromes [22–24]. IFI16
protein is also a target for autoantibodies. Anti-IFI16 autoanti-
bodies have been demonstrated in the sera of patients affected by
systemic autoimmune diseases including SLE, SSc, and SjS. [25–
28]. To explain this observation, we hypothesized that its
overexpression and extranuclear appearance during cell death
contribute to its release into the extracellular milieu and eventually
to the induction of specific autoantibodies. Consistent with this
hypothesis, we have recently demonstrated in vitro that the IFI16
protein, normally detected in the nucleus of human keratinocytes,
can be induced to appear in the cytoplasm under conditions of UV
light-induced cell injury and then released in the culture media. A
similar situation was also found in tissue sections of skin biopsies
from patients with SLE. In this model, IFI16 expression was up-
regulated and mislocalized to the cytoplasm, suggesting that
aberrant expression of IFI16 in epithelial and inflammatory cells
can also play a role in triggering an autoimmune response in vivo
[29]. However, since IFI16 was previously thought to be restricted
to the intracellular environment, and in particular to the nucleus
[13,30], all the recognized biological activities of IFI16, as well as
their possible links with human pathologies, have only been
considered in relation to this localization. Indeed, all the in vitro
studies published to date have involved the overexpressing or
down-regulation of IFI16 in different cell models, and the
modulation of IFI16 has always been monitored intracellularly
(i.e. using cell extracts or by directly analyzing the presence of
IFI16 inside the cells, for instance using immunofluorescence
techniques).
In the present study, using an in-house enzyme-linked
immunosorbent assay (ELISA) we demonstrate the presence of
detectable amounts of a circulating form of IFI16 in the sera from
patients affected by autoimmune disorders. We also provide
experimental evidence showing that the extracellular form of
IFI16 is directly involved in specifically down-regulating the
migratory activities and tube morphogenesis of endothelial cells.
Moreover, we demonstrate the ability of IFI16 to bind to the
plasma membrane of endothelial cells and, by means of binding
kinetics analyses, we show for the first time, evidence of high
affinity IFI16 binding sites on these cells. These data point to a




Human umbilical vein endothelial cells (HUVECs), were grown
in Endothelial cell growth medium-2 (EGM-2) (Lonza, Italy) with
2% Fetal Bovine Serum (Sigma-Aldrich, Milan, Italy) and
supplemented with 1% Penicillin-Streptomycin solution (Sigma-
Aldrich, Milan, Italy) as previously described [31]. Low passage
human dermal fibroblasts, HDF (ATCC), mouse fibroblasts, 3T3
(ATCC), HeLa (ATCC) and HaCaT (ATCC) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich,
Milan, Italy) supplemented with 10% fetal bovine serum and 2%
Penicillin-Streptomycin solution Unless specified, all cells were
grown at 37uC and 5% CO2.
Recombinant Proteins
The entire coding sequence of the b isoform of human IFI16
was subcloned into the pET30a expression vector (Novagen,
Madison, WI) containing an N-terminal histidine tag. Protein
Expression and affinity purification, followed by fast protein liquid
chromatography (FPLC), were performed according to standard
procedures. The purity of the proteins was assessed by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis. As
negative controls in enzyme-linked immunosorbent assays
(ELISA), the polypeptide encoded by the pET30a empty vector
(control peptide) was expressed and purified according to the same
protocol.
Patients and Determination of Human Extracellular IFI16
by Capture ELISA
The study groups comprised patients suffering from Systemic
Sclerosis, (n = 50), Systemic Lupus Erythematosus, (n = 100),
Sjogren Syndrome, (n = 49), Rheumatoid Arthritis (n = 50) and
Non-SLE Glomerulonephritis (n = 46). As controls, we investigat-
ed sera from 116 sex- and age-matched healthy subjects. Written
informed consent was obtained from all subjects according to the
Declaration of Helsinki and approval was obtained from local
ethics committees of corresponding hospital.
For the determination of circulating extracellular IFI16, a
capture ELISA was employed. Briefly, polystyrene micro-well
plates (Nunc-Immuno MaxiSorp; Nunc, Roskilde, Denmark) were
coated with a home-made polyclonal rabbit-anti-IFI16 antibody
(478–729 aa). Subsequently, plates were washed and free binding
sites then saturated with PBS/0.05% Tween/3% BSA. After
blocking, sera were added to plates in duplicate. Purified 6His-
IFI16 protein was used as the standard and BSA served as the
negative control. The samples were washed, monoclonal mouse
anti-IFI16 antibody (Santa Cruz, sc-8023) added, and then
incubated for 1 h at room temperature. After washing, horseradish
peroxidase-conjugated anti-mouse antibody (GE Healthcare Eu-
rope GmbH, Milan, Italy) was added. Following the addition of
the substrate (TMB; KPL, Gaithersburg, MD, USA), absorbance
was measured at 450 nm using a microplate reader (TECAN,
Mannedorf, Switzerland). Concentrations of extracellular IFI16
were determined using a standard curve for which increasing
concentrations of purified 6His-IFI16 were used.
Cell Viability Assay
Cells were seeded at a density of 16104/well in a 96-well culture
plate. After 24 hours, cells were treated with different doses (10, 25
or 50 mg/ml) of recombinant IFI16 protein (IFI16), mock-treated
using the same volume of vehicle as each IFI16 dose (Mock), or left
untreated (NT). Where indicated, different doses (1.75 mgr or
3.5 mgr) of antibody against IFI16 were added. Forty-eight hours
after treatment, cell viability was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma-Aldrich, Milan, Italy) method, as previously described [32].
Tube Morphogenesis Assay
HUVEC were seeded in complete medium in 60-mm culture
dishes coated with 0.2% gelatin (Sigma-Aldrich, Milan, Italy) and
were treated for 48 h with different doses (10 or 25 mg/ml) of
recombinant IFI16 protein (IFI16). As negative controls, cells were
treated with the same volumes of vehicle (Mock) used for each
IFI16 dose or left untreated (NT). Where indicated, different doses
Extracellular IFI16 Protein as Signal of Damage
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(1.75 mgr or 3.5 mgr) of antibody against IFI16 were added. Tube
morphogenesis assay was performed as described in [33]. Briefly, a
24-microwell plate, pre-chilled at 220uC, was coated with 250 ml/
well of Matrigel Basement Membrane (5 mg/ml; Becton and
Dickinson, Milan, Italy) and then incubated at 37uC for 30 min
until solidified. HUVEC (86104 cells/500 ml per well) were seeded
onto the matrix and allowed to incubate at 37uC in 5% CO2.
Plates were photographed after 6 h using a Leica inverted
microscope.
Migration Assay
Twenty-four well transwell inserts with an 8 mm pore size
(Corning B.V. Life Sciences, Amsterdam, The Netherlands) were
coated with a thin layer of gelatin (0.2%). HUVECs cultured in
EGM-2 with 2% FBS and pre-treated with different concentra-
tions of IFI16 recombinant protein or mock- or untreated for 48
hours were washed twice with PBS, trypsinized and plated into the
upper chambers (46105 cells) resuspended in 200 ml of EBM-2
(Lonza, Italy), 0.1% BSA (Sigma-Aldrich, Milan, Italy) plus IFI16
recombinant protein or mock solution (the same amounts as in the
48 h pre-treatment). The lower chambers were filled with 600 ml
EGM2 containing VEGF and bFGF (as chemo-attractants)
(Sigma-Aldrich, Milan, Italy), 2% FBS, and IFI16 recombinant
protein or mock solution (the same amounts as in the upper
chamber). The chambers were incubated for 5 h at 37uC in a
humidified atmosphere containing 5% CO2. After incubation,
cells on the upper side of the filter were removed. The cells that
had migrated to the lower side of the filter were washed twice with
PBS, fixed with 2.5% glutaraldehyde (Sigma-Aldrich, Milan, Italy)
for 20 min at room temperature, and stained with 0.5 ml crystal
violet (0.1% in 20% methyl alcohol solution) (Sigma-Aldrich,
Milan, Italy). After washes, color was developed in 10% acetic acid
and read in duplicate at 540 nm on a microplate reader (Victor 3;
Perkin-Elmer, Boston, MA).
rIFI16-FITC Membrane Binding and Confocal Microscopy
HUVEC were seeded in 24-well plate in the presence of glass
cover-slip and were grown overnight in presence of 1 mg/ml
tunicamycin (Sigma-Aldrich, Milan, Italy) in EGM-2 medium with
2% FBS and antibiotics. The cells were washed twice with cold
PBS and incubated with increasing concentrations (10 nM,
20 nM, 30 nM) of FITC labeled rIFI16 (FluoReporterH FITC
Protein Labeling Kit by Invitrogen) for 90 minutes at 4uC. Later
the cells were washed twice with cold PBS and were fixed using
2% para-formaldehyde solution for 4 minutes. The PBS wash was
repeated thrice and the coverslips were mounted on glass slides
using ProLongH Gold Antifade Reagent by Invitrogen. The slides
were observed using Leica Confocal Microscope at 490 nm
excitation wavelength for FITC in one channel while trans-
illuminated light in the other.
Co-Culturing and Immunofluorescence
Co-culturing was performed with HeLa cells and HUVEC, as
described in Koristka S. et.al [34]. 105 HeLa cells were seeded in
24 well-plate coated with 0.2% Gelatin in the presence of glass
cover-slip and grown over-night in DMEM with 10% FCS at
37uC, 5% CO2. The cells were washed, suspended in PBS and
lethally irradiated with UV-B lamp (HD 9021; Delta Ohm S.r.l.,
Padova, Italy). The dosage of 1000 Wm2 was counted using a
UVB irradiance meter cosine corrector with spectral range of 280–
319 nm (LP 9021 RAD; Delta Ohm). Followed by this, 56104
HUVEC were added in the same well, grown in EGM-2 with 2%
FCS until ready. Immunofluorescence was performed after 24 hr,
36 hr and 48 hr using a home-made anti-IFI16 polyclonal as
primary antibody and Alexa488- anti-rabbit (GE Healthcare) as
secondary antibody. The cells were then fixed with 2% para-
formaldehyde (Sigma-Aldrich, Milan, Italy), permeabilized with
0.2% Triton X-100 (Sigma-Aldrich, Milan, Italy) and nuclear
stained with 1 mg/ml propidium iodide (Sigma-Aldrich, Milan,
Italy). The coverslips were mounted on glass slides using ProLongH
Gold Antifade Reagent by Invitrogen and the cells were observed
by Leica confocal microscope.
Radioiodination of rIFI16 and Binding Assays
Iodination Beads were purchased from Thermo Fischer
Scientific Inc. (Rockford, IL, USA) and used according to
manufacturer’s instructions. Briefly, two dry beads were washed
with rIFI16 elution buffer (50 mM HEPES pH 7.5; 1 M NaCl)
(Sigma-Aldrich, Milan, Italy), soaked dry and was incubated for 5
minutes with the solution of carrier-free 2 mCi Na125I (Perkin
Elmer Italia, Milan, Italy) and diluted in elution buffer. Later
200 mg of rIFI16 was added and incubated for 15 minutes. The
labeling reaction was passed through Zeba Spin Desalting
Columns (Thermo Fischer Scientific Inc.) to remove excess
Na125I or unincorporated 125I from the iodinated protein. The
concentration of the final radioiodinated [125I]-rIFI16 was
calculated using the following formula, where ‘C’ is the cpm
counted, ‘V’ is volume of solution counted in ml and ‘Y’ is the
specific activity of the radioligand in cpm/fmol.
Concentration of [125I]-rIFI16 in (pM) = [‘C’cpm/‘Y’cpm/
fmol]/‘V’ml.
Binding assay was performed as described in [35,36], 105 cells/
well were seeded and attached in a 24-well plate with. Once ready,
the medium was removed and the cells were washed with PBS.
Further they were re-suspended with increasing concentrations of
[125I]-rIFI16 (1–32 nM) within different wells in the presence of
200 nM unlabeled rIFI16 for Non-Specific Binding. Separately,
other wells were re-suspended with [125I]-rIFI16 (1–32 nM)
without any unlabeled rIFI16 for total binding. The incubation
was performed at 4uC for 90 minutes. Later, the cells were washed
with PBS to remove any loosely bound ligand and were then
suspended in warm 1% SDS (Sigma-Aldrich, Milan, Italy) for 5
minutes. The SDS lysate of the cells was then measured on Cobra
II Series Auto-Gamma Counter. All the experiments were carried
out in triplicates and the data was analyzed using non-linear
regression equations from GraphPad Prism with 95% confidence
intervals.
Competition and Inhibition of [125I]-rIFI16 Binding
For binding competition experiments, cells were seeded into 96-
well plates at a density of 104 cells/well. The medium was
removed and cells were washed with PBS. HUVEC were then
incubated at 4uC for 90 minutes with unlabeled rIFI16 (10–
1000 nM) in the presence of 10 nM [125I]-rIFI16. Binding
inhibition was carried out overnight by incubating 10 nM [125I]-
rIFI16 with varying concentrations (10–1000 nM) of anti-IFI16
polyclonal N-terminal (1–205 aa) or C-terminal (478–729 aa)
antibodies at 4uC. This mixture was then added to 104 HUVEC
and incubated for 90 minutes at 4uC. The loosely bound ligand
was removed by washing twice with PBS, and cells were then
detached using warm 1% SDS and the levels of [125]-rIFI16-
binding to HUVEC assessed using a Cobra II Series Auto-Gamma
Counter. The data were analyzed using non-linear regression
equations in GraphPad Prism under 95% confidence intervals.
Statistical Analysis
All statistical tests were performed using GraphPad Prism
version 5.00 for Windows (GraphPad, La Jolla, CA, USA).
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Positivity cut-off values for anti-IFI16 antibodies were calculated
as the 95th percentile for the control population and the Kruskal-
Wallis test was used to measure associations. To test the effects of
recombinant IFI16 protein (rIFI16) on biological functions of
primary endothelial cells one-way analysis of variance (ANOVA)
with Bonferroni adjustment for multiple comparisons was used.
Results
Serum Levels of IFI16 Protein are Increased in Patients
with Systemic Autoimmune Diseases
Sera were harvested from patients suffering from systemic
autoimmune diseases characterized by endothelial dysfunction,
including SSc, SLE, SjS, and RA. IFI16 serum levels were
quantified using an in-house sandwich ELISA and compared with
age- and sex-matched healthy controls. All absorbance levels were
in the range of assay linearity. With the cut-off value set to the 95th
percentile of the control population (27 ng/ml), mean IFI16 levels
were significantly increased in patients with SSc, SLE, RA, and
SjS compared to the control group (4.7 ng/ml) (SSc: 25.4 ng/ml,
p,0.001; SLE: 23.5 ng/ml, p,0.001; RA: 222 ng/ml, p,0.001;
SjS: 88.2 ng/ml, p,0.001). Of note, the sera from RA patients
displayed the highest levels of circulating free protein. IFI16 levels
above the 95th percentile for control subjects were observed in
34% of SSc, 37% of SLE, 47% of SjS, and 56% of RA patients
(Figure 1). By contrast, IFI16 levels in non-SLE GN patients did
not show any significant difference in comparison with healthy
controls. Since the objective of this part of the study was limited to
demonstrate the presence of circulating IFI16 in patients’ sera for
justifying the rest of the in vitro studies, correlation with
clinicopathological parameters was behind the aim of these studies
and was not performed.
Effects of Extracellular IFI16 on Different Functions of
Primary Endothelial Cells
Abnormalities in angiogenesis are frequently present in systemic
autoimmune diseases and may lead to tissue damage and
premature vascular disease [37]. To verify whether extracellular
IFI16 was also involved in this pathogenic process, HUVEC were
treated with increasing concentrations of recombinant IFI16
protein (rIFI16) (10, 25 or 50 mg/ml), mock-treated with the same
volumes of vehicle (Mock), or left untreated (NT) and then assessed
for cell viability at 48 hours incubation time by MTT assay. As
shown in Figure 2A, the addition of endotoxin-free rIFI16 protein
did not reduce the amount of viable adherent cells when compared
to mock or untreated cells at the concentration of 10 and 25 mg/
ml, respectively. At the highest concentration used (50 mg/ml), a
slight reduction in cell viability was observed, and consequently
the following studies were conducted with the lower doses.
Next, to test whether the addition of rIFI16 to culture media
altered other biological parameters of endothelial cells, HUVEC
were treated as described for the assessment of cell viability (MTT
assay) and then analyzed for their tubule morphogenesis and
chemotactic activities. As shown in Figure 2B, exogenous
administration of 25 mg/ml rIFI16 severely limited tubulogenesis,
with most cells generating incomplete tubules or aggregating into
clumps. The extent of angiogenesis was quantified by counting the
intact capillary-like tubules called as Lumens, which showed 75%
decrease in its numerical value, as well as the number of
interconnecting branch points showing 77% decrease.
(Figure 2B). These effects were less pronounced when a lower
dose of 10 mg/ml rIFI16 was used with 22% and 15% decrease
respectively. In contrast, untreated or mock-treated HUVEC
plated onto matrigel supported the formation of an extensive
interconnecting polygonal capillary-like network.
Next, we evaluated the effects of rIFI16 on the migration phase
of angiogenesis in a transwell migration assay routinely used to
study cell migration in response to specific stimuli. HUVECs
untreated, mock-treated, or incubated with rIFI16 (10 or 25 mg/
ml) for 48 h were transferred into transwell migration chambers.
As shown in Fig. 2C, only a small population of HUVECs cultured
in the presence of 25 mg/ml rIFI16 were able to migrate through
the chamber (30% of migration), whereas mock-treatment resulted
in considerable migration (95% and 87% for 10 mg/ml and
25 mg/ml, respectively).
Taken together, these results demonstrate the capability of
extracellular rIFI16 to impair physiological functions of endothe-
lial cells, such as the differentiation phases responsible for tube
morphogenesis and migration.
Anti-N-terminus IFI16 Antibodies Neutralize the
Cytotoxic Activity of IFI16
To demonstrate that the effects exerted by IFI16 protein on
target cells were specific and not a consequence of cell cytotoxicity,
HUVEC were treated with 25 mg/ml rIFI16 in the presence or
absence of specific rabbit polyclonal antibodies recognizing the N-
terminal or the C-terminal domain of IFI16 protein. HUVEC
incubated with rIFI16 in the presence of normal rabbit IgG were
used as the positive control. As described in the previous section,
rIFI16 severely affected the capability of endothelial cells to
generate microtubules as well as their transwell migration activity,
while the same effects were observed in presence of normal rabbit
IgG (Figure 3A and 3B). In contrast, the presence of anti-N-
terminus antibodies reduced the Lumens by 16%, Branch Points
by 5% and migration by 1% while anti-C-terminus antibodies
reduced the Lumens by 60%, Branch Points by 32% and
Figure 1. IFI16 protein levels in patients’ and controls’ sera
determined using an in-house capture ELISA. Each dot represents
the concentration of IFI16 protein (expressed in ng/ml on a linear scale)
in each individual subject: patients suffering from Systemic Sclerosis
(SSc, n = 50), Systemic Lupus Erythematosus (SLE, n = 100), Sjogren’s
Syndrome (SjS, n = 49), Rheumatoid Arthritis (RA, n = 50), and non-SLE
glomerulonephritis (non-SLE GN n = 46) were investigated together
with healthy controls (CTRL, n = 116). The horizontal bars represent the
median values. Values over the dotted line indicate the percentage of
subjects with IFI16 protein levels above the cut-off value (27 ng/ml)
calculated as the 95th percentile of the control population. Statistical
significance: *** p,0.001 vs. controls (Kruskall-Wallis test).
doi:10.1371/journal.pone.0063045.g001
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migration by 49%. This indicates the role of anti-N-terminus
antibody in inhibiting the activities of IFI16 toward endothelial
cells, restoring the tube formation and migratory activities.
Altogether, these results suggest that the IFI16 activity is specific
and that the functional domain resides at the N-terminus, where
the PYD domain is localized.
Binding of Extracellular IFI16 on the Plasma Membrane of
HUVEC
The finding that extracellular IFI16 impairs endothelial cell
functions, including tube morphogenesis and transwell migration
indicates a possible alarmin function as recently demonstrated for
Danger and Pathogen-associated molecular pattern molecules
collectively called as DAMPs, PAMPs such as autoantigen
HMGB-1 [38,39]. Thus to find evidence in this direction it was
important to evaluate the binding interaction of IFI16 on the
plasma membrane of HUVEC. A series of binding experiments
were conducted to verify the presence of high-affinity binding sites
in the membranes of the target cells. In the previous section, it has
been described that 25 mg/ml (300 nM) rIFI16 concentration is
non-toxic to HUVEC, while they can still perform biological
functions. Thus HUVEC were incubated with lowest concentra-
tions (10 nM, 20 nM, and 30 nM) of FITC-labeled rIFI16 to
avoid toxicity or apoptosis and the binding was visualized by
confocal microscopy. As shown in Figure 4A, binding of FITC-
labeled rIFI16 was detected at least concentration of 10 nM,
increased at 20 nM, and saturated at 30 nM. To avoid the non-
specific binding of rIFI16 with sugar residues on plasma
membrane, HUVEC were grown in presence of tunicamycin
which inhibits N-glycosylation of proteins. By contrast to above
findings, human fibroblasts were negative for FITC-labeled rIFI16
at all the rIFI16 concentrations investigated (data not shown).
Furthermore, to demonstrate that the binding of rIFI16 is of
physiological relevance, co-culturing experiments were organized
in such a way that UV-B irradiated cells release endogenous IFI16
[29] which in turn binds to neighboring HUVEC in the same
system. As shown in Figure 4B, after 24 h HUVEC were observed
to be surface bound with endogenous IFI16 released from HeLa
cells, while by 36 h this bound IFI16 entered the cytoplasm and by
48 h it almost disappeared. When fibroblasts were used instead of
HUVEC, the binding was not observed, while also when HUVEC
were cultured with normal HeLa cells, surface presence of IFI16
was not detected (data not shown).
Kinetics of rIFI16 Binding on Different Cell Lines
To get some insights into the binding characteristics of IFI16 to
different cell lines, binding kinetics experiments using radioiodin-
ated rIFI16 were performed. Specific binding was calculated as the
difference between total and non-specific binding. As shown in
Figure 5A, the specific binding of [125I]-rIFI16 to its binding site
on HUVEC is saturable and has a dissociation constant (Kd) equal
to 2.7 nM; 71.55 to 83.84 fmol of [125I]-rIFI16 was estimated to
saturate the binding sites on 105 HUVEC, thus the maximal
number of binding sites (Bmax) could be estimated to be in the
range of 250,000 to 450,000 binding sites/cell. Furthermore, the
binding of [125I]-rIFI16 on HUVEC was displaced by 10- to 100-
fold of unlabeled rIFI16, demonstrating its competitive nature
(Figure 5B). The inhibition constant (Ki) was calculated to be
14.43 nM and the half maximal inhibitory concentration (IC50)
was 67.88 nM. Similar results were obtained for HeLa and
HaCaT cell lines, which also indicated saturable and competitive
nature towards rIFI16 binding. As a negative control, human
dermal fibroblasts (HDF) and murine fibroblasts (3T3) were
accessed for specific and competitive binding of [125I]-rIFI16 in
parallel with HUVEC (Figure 5A and 5B). Both HDF and 3T3
were found to exhibit non-saturable rIFI16 binding, indicating the
lack of any specific IFI16 binding sites. Moreover, the binding of
rIFI16 on these cells was non-competitive in nature (Figure 5B).
Also as reported in Figure 5C, different cell lines shown variable
affinities towards IFI16 binding.
[125I]-rIFI16 Binding Inhibition by Anti-IFI16 Polyclonal
Antibodies
To evaluate the binding properties of rIFI16 to its receptor with
respect to epitope mapping, we performed a binding inhibition
assay using radioiodinated rIFI16 in the presence of increasing
concentrations of antibodies recognizing the IFI16 N-terminal
domain. As depicted in Figure 6, a gradual decrease in the bound
[125I]-rIFI16 was observed with increasing concentrations of
antibody (from 10 to 1000 nM). Conversely, the anti-IFI16
antibody recognizing the C-terminal domain (478–729 aa) was
not able to inhibit the binding of [125I]-rIFI16 to its receptor.
Together with the results from the functional assays, these
observations provide evidence indicating that the N-terminal
region of rIFI16 is required for its binding to the novel membrane
receptor on HUVEC and is responsible for its signal transduction
capacity.
Discussion
In the present study, we demonstrate for the first time: i) the
presence of significant levels of extracellular IFI16 protein in the
sera of patients affected by systemic autoimmune diseases,
including SSc, SjS, SLE and RA but not in non-SLE GN as
compared to healthy controls, and ii) that the extracellular IFI16
exerts biological effects on endothelial cells upon binding to a
specific cell surface receptor. These findings have important
implications as they provide novel insights into the role of IFI16 in
the pathogenesis of systemic autoimmune diseases. Various
research groups, including ours, have shown that following
transfection of virus-derived DNA [19,40], or treatment with
UVB [29], IFI16 delocalizes from the nucleus to the cytoplasm
and is then eventually released into the extracellular milieu.
Consistent with these observations, we now demonstrate the
presence of circulating IFI16 protein in the sera of patients affected
by systemic autoimmune diseases, but not in patients with non-
autoimmune inflammatory diseases like non-SLE GN. Skin
manifestations and vasculopathy are common components of a
number of autoimmune diseases and represent a significant source
of morbidity [41,42]. Thus, to investigate the hypothesis that
circulating IFI16 is able to exert harmful effects on target cells
in vivo, an in vitro cell model consisting of primary endothelial cells
Figure 2. Extracellular IFI16 affects various biological functions of primary endothelial cells. HUVEC were treated with different doses of
recombinant IFI16 protein (rIFI16), the same volumes of vehicle (Mock), or left untreated (NT) for 48 h. (A) Viability analysis (MTT assay); the viability of
control preparations (NT) was set to 100%. (B) Capillary-like tube formation assay (Matrigel). For a quantitative assessment of angiogenesis, the
number of lumens and branch points was assessed (upper panels); representative images of three independent experiments are reported (lower
panels). (C) Migration analysis (Transwell assay) results are reported as the percentage of migrated cells vs. untreated HUVECs. Values represent the
mean6SD of 3 independent experiments, (**p,0.01, ***p,0.001; one-way ANOVA followed by Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0063045.g002
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(HUVEC) was used to test the activity of extracellular IFI16 on cell
functions. These experiments clearly demonstrate that extracellu-
lar IFI16 affects some biological processes of endothelial cells,
including tube morphogenesis and transwell migration. The
specificity of these effects was assessed by the addition of anti-
IFI16 antibodies which were able to neutralize the activity of the
protein blocking its inhibitory effects. Subsequently, the presence
of IFI16 in the extracellular environment could also be the main
Figure 3. Anti-IFI16 antibodies restore the biological activities of extracellular IFI16. HUVEC were treated for 48 h with different doses of
recombinant IFI16 protein (rIFI16), the same volumes of vehicle (Mock), or left untreated (NT), alone or in combination with antibodies against IFI16.
(A) Capillary-like tube formation assay (Matrigel). For a quantitative assessment of angiogenesis, the number of lumens and branch points was
assessed (upper panels); representative images of three independent experiments are reported (lower panels). (B) Migration analysis (Transwell assay)
results are reported as the percentage of migrated cells vs. untreated HUVECs. Values represent the mean6SD of 3 independent experiments
(**p,0.01, ***p,0.001, one-way ANOVA followed by Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0063045.g003
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reason behind the presence of anti-IFI16 autoantibodies in
autoimmune patients’ sera. (Caneparo et al. Lupus 2013, accept-
ed) Together, these observations suggest the possible role of IFI16
in the clinical manifestation of autoimmune diseases, due to its
presence in the extracellular environment. Since IFI16 can be
released extracellularly which further reflect distinct extracellular
biological activities, it is an indication of a novel alarmin function
of this interferon inducible protein. Such stress-dependent
shuttling, release, binding to cell surface was described in the past
for autoantigen La/SS-B [43] and recently reviewed for HMGB1
protein [39] which upon release, binds to the cell surface receptors
of neighboring cells. Thus as part of alarmin function, we further
hypothesized that once released IFI16 protein must also bind
neighboring cells to communicate the stress signal. In this
direction, we assessed the affinity of IFI16 towards the plasma
membrane of HUVEC. Confocal images visualized patterned
binding of FITC labeled rIFI16 protein on the plasma membrane,
which gave us the first preliminary evidence of the existence of an
IFI16 interacting molecule which we suspect to be receptor-kind.
Furthermore, we found experimental evidence that endogenous
IFI16 protein released by dying cells bind neighboring cells. As a
consequence of this binding, time-lapse studies proved its further
entry into the cytoplasm. Moreover, such binding and transport of
IFI16 was observed in different cell lines with different affinities.
The experiments using radiolabeled IFI16 to investigate the
binding kinetics of IFI16 in the HUVEC provide strong evidence
supporting the presence of specific binding sites in the plasma
membrane through which IFI16 exerts its cytotoxic activity. These
binding sites were found to be saturable and competitive for IFI16,
while the binding experiments in HUVEC indicate the presence of
approximately 250,000 to 450,000 binding sites per cell, with a
dissociation constant (Kd) of 2.7 nM. Similar binding character-
Figure 4. Plasma membrane binding of IFI16 to HUVEC. (A) Cells were left untreated (a, negative control) or incubated with increasing
concentrations of FITC-labeled recombinant IFI16 (b, 10 nM rIFI16-FITC; c, 20 nM rIFI16-FITC; d, 30 nM rIFI16-FITC). Binding was detected by confocal
microscopy using an excitation wavelength of 490 nm for FITC in one channel and trans-illuminated light in the other. Representative images of three
independent experiments are shown. (B) Endogenous IFI16 released by irradiated HeLa cells binds neighboring HUVEC. UV-B irradiated HeLa cells
were co-cultured with HUVEC and after 24 h, 36 h and 48 h, dead cell debris were removed and immunofluorescence was performed on the
remaining live HUVEC using a home-made anti-IFI16 polyclonal as primary antibody and Alexa-488- anti-rabbit as secondary antibody. The cells were
then fixed, permeabilized, nuclear-stained using propidium iodide and analyzed by confocal microscopy. Fibroblasts were employed as negative
control. Representative images of three independent experiments are shown.
doi:10.1371/journal.pone.0063045.g004
Figure 5. Binding Kinetics of [125I]-rIFI16 on HUVEC, HDF, and 3T3 cells. (A) Specific binding of [125I]-rIFI16 on the plasma membrane of
HUVEC, HeLa, HACAT, HDF, and 3T3 cells. (B) Competitive binding of [125I]-rIFI16 on HUVEC, HeLa, HaCaT, HDF, and 3T3 cells. (C) The binding affinity
(Kd), total bound ligand (Bmax) and the estimated number of binding sites per cell for different cell lines. The experiment was carried out in triplicates
and data was analyzed using non-linear regression equations from GraphPad Prism with 95% confidence intervals. All the experiments have been
repeated at least three times and one representative is reported.
doi:10.1371/journal.pone.0063045.g005
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istics were shown by different epithelial cell lines while a
completely un-related cell line like fibroblasts demonstrated non-
specific binding. This explains the specificity of IFI16 binding
which is mostly restricted towards endothelium and epithelium.
Neutralization experiments employing antibodies directed against
different regions of the protein allowed us to demonstrate that the
N-terminus, containing the PYD domain, is responsible for
binding interaction. Consistent with this observation, the same
antibodies were able to neutralize the biological activity of
extracellular IFI16, as described earlier.
In summary, our results provide evidence for a novel alarmin
function of IFI16 protein which is overexpressed upon inflamma-
tory stimuli and then released in the extracellular environment.
Once released, IFI16 binds to neighboring cells propagating the
stress signal causing damage. The presence of anti-IFI16
autoantibodies have been detected in many autoimmune diseases
[25–28], thus the release of IFI16 in the extracellular milieu marks
the first step in the development of autoimmunity.
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Early stage IFI16 cytoplasmic translocation and late stage entrapment into egressing virions during HCMV 
infection
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Intrinsic immune mechanisms mediated by constitutively expressed proteins termed "restriction factors" provide 
frontline antiviral defense. We recently demonstrated that the DNA sensor IFI16 restricts HCMV replication by 
down-regulating viral early and late but not immediate-early mRNAs and their protein expression. Here, we show 
that at an early time point during the in vitro infection of low-passage human embryonic lung fibroblasts (HELF), 
IFI16 binds to HCMV DNA. However, during a later phase following infection, IFI16 is mislocalized to the 
cytoplasmic virus assembly complex (AC), where it colocalizes with viral structural proteins. Indeed, upon its 
binding to pUL97, IFI16 undergoes phosphorylation and relocalizes to the cytoplasm of HCMV-infected cells. 
ESCRT (Endosomal Sorting Complex Required for Transport) machinery regulates the translocation of IFI16 into 
the virus AC by sorting and trafficking IFI16 into multivesicular bodies (MVB), as demonstrated by the interaction of 
IFI16 with two MVB markers: Vps4 and TGN46. Finally, IFI16 becomes incorporated into the newly assembled 
virions as demonstrated by Western blot analysis of purified virions and electron microscopy. Together, these 
results suggest that HCMV has evolved mechanisms to mislocalize and hijack IFI16, trapping it within mature 
virions. However, the significance of this IFI16 trapping following nuclear mislocalization remains to be established. 
Intracellular viral DNA sensors and restriction factors are critical components of host defence, which alarm and 
sensitize immune system against intruding pathogens. We have recently demonstrated that the DNA sensor IFI16 
restricts HCMV replication by down-regulating viral early and late but not immediate-early mRNAs and their protein 
expression. However, viruses are known to evolve numerous strategies to cope and counteract such restriction 
factors and neutralize the first line of host defence mechanisms. Our findings describe that during early stages of 
infection, IFI16 successfully recognizes HCMV DNA. However, in late stages HCMV mislocalizes IFI16 into the 
cytoplasmic viral assembly complex (AC) and finally entraps the protein into mature virions. This work clarifies the 
mechanisms HCMV relies to overcome intracellular viral restriction, which provides new insights about the 
relevance of DNA sensors during HCMV infection.
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Intrinsic immune mechanisms mediated by constitutively expressed proteins termed “restriction 23 
factors” provide frontline antiviral defense. We recently demonstrated that the DNA sensor IFI16 24 
restricts HCMV replication by down-regulating viral early and late but not immediate-early mRNAs 25 
and their protein expression. Here, we show that at an early time point during the in vitro infection of 26 
low-passage human embryonic lung fibroblasts (HELF), IFI16 binds to HCMV DNA. However, during 27 
a later phase following infection, IFI16 is mislocalized to the cytoplasmic virus assembly complex 28 
(AC), where it colocalizes with viral structural proteins. Indeed, upon its binding to pUL97, IFI16 29 
undergoes phosphorylation and relocalizes to the cytoplasm of HCMV-infected cells. ESCRT 30 
(Endosomal Sorting Complex Required for Transport) machinery regulates the translocation of IFI16 31 
into the virus AC by sorting and trafficking IFI16 into multivesicular bodies (MVB), as demonstrated 32 
by the interaction of IFI16 with two MVB markers: Vps4 and TGN46. Finally, IFI16 becomes 33 
incorporated into the newly assembled virions as demonstrated by Western blot analysis of purified 34 
virions and electron microscopy. Together, these results suggest that HCMV has evolved mechanisms 35 
to mislocalize and hijack IFI16, trapping it within mature virions. However, the significance of this 36 











Intracellular viral DNA sensors and restriction factors are critical components of host defence, which 47 
alarm and sensitize immune system against intruding pathogens. We have recently demonstrated that 48 
the DNA sensor IFI16 restricts HCMV replication by down-regulating viral early and late but not 49 
immediate-early mRNAs and their protein expression. However, viruses are known to evolve numerous 50 
strategies to cope and counteract such restriction factors and neutralize the first line of host defence 51 
mechanisms. Our findings describe that during early stages of infection, IFI16 successfully recognizes 52 
HCMV DNA. However, in late stages HCMV mislocalizes IFI16 into the cytoplasmic viral assembly 53 
complex (AC) and finally entraps the protein into mature virions. This work clarifies the mechanisms 54 
HCMV relies to overcome intracellular viral restriction, which provides new insights about the 55 





Intrinsic immunity constitutes a frontline antiviral defense system mediated by constitutively expressed 60 
proteins, termed restriction factors (RF), that are already present and active before a virus enters a cell 61 
(1, 2). The term “restriction factor” was originally adopted by investigators studying retroviruses. In the 62 
case of primate lentiviruses, the proteins TRIM5a and tetherin (CD317, BST/HMI), as well as members 63 
of the APOBEC family of cytidine deaminases, are prominent examples of host cell factors that can 64 
restrict the replication of human immunodeficiency virus type 1 (HIV-1) at distinct steps of the viral 65 
life cycle. However, HIV-1 has evolved evasion strategies to counter all of these factors. One evasion 66 
strategy that viruses may use is to exploit the effects of a RF for its own purposes, or to generate an 67 
interfering protein that neutralizes the effect of a RF. Another strategy involves the virus hijacking a 68 
RF during its phase of maturation to guarantee protection (reviewed in 3, 4). While the interference of 69 
retroviral replication by cellular RFs and retroviral evasion strategies have been studied in great detail, 70 
research into the ways through which RFs restrict other viral infections, such as rhabdoviruses, 71 
filoviruses, influenza viruses, hepatitis C virus, and herpesviruses, is still in its infancy (reviewed in 5). 72 
In particular, in the case of the human cytomegalovirus (HCMV), a β-herpesvirus, the cellular 73 
components of nuclear domains 10 (ND10s) (i.e. promyelocytic leukemia protein (PML), hDaxx, and 74 
Sp100) have been identified as restriction factors that are involved in mediating intrinsic immunity 75 
against this virus (6-8). 76 
 The IFI16 protein, a member of the p200 family of proteins, now designated the PYHIN family, 77 
contains an N-terminal PYRIN domain (PYD) and two partially conserved 200 amino acid-long 78 
domains (HIN domains). IFI16 displays multifaceted activity due to its ability to bind to various target 79 
proteins (i.e. transcription factors, signaling proteins, and tumor suppressor proteins) and to modulate 80 
various cell functions (9). In addition, IFI16 has been shown to bind to and function as a pattern 81 
recognition receptor (PRR) of virus-derived intracellular DNA, and trigger the expression of antiviral 82 
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cytokines via the STING-TBK1-IRF3 signaling pathway (10-20). Although many different functions 83 
have been ascribed to IFI16 (and to other proteins of the PYHIN family), its role as an antiviral 84 
restriction factor has not yet been fully described. Recent studies from our laboratory implicate the 85 
involvement of IFI16 in host defense against HCMV (21). The evidence supporting such a role of 86 
IFI16 is as follows: (i) small interfering RNA (siRNA)-mediated depletion of IFI16 in primary human 87 
embryonic lung fibroblasts (HELF) significantly increases HCMV replication efficiency as a result of 88 
augmented viral DNA synthesis; (ii) similarly, viral plaque formation is enhanced in the presence of an 89 
exogenous dominant-negative IFI16 mutant that competes with the endogenous IFI16; (iii) 90 
overexpression of functional IFI16 in HCMV-infected HELFs decreases both virus yield and viral 91 
DNA copy number; and (iv) early and late, but not immediate-early viral mRNAs and proteins are 92 
strongly down-regulated under these same conditions, suggesting that IFI16 exerts its main antiviral 93 
effect at the level of viral genome synthesis. This unique defense mechanism distinguishes the activity 94 
of IFI16 from that described for ND10.  95 
In more general terms, human viruses have to face powerful RF responses and thus have 96 
evolved a number of strategies to overcome RF attack. Viral antagonists can act through highly 97 
specialized mechanisms, such as coupling RFs to protein degradation pathways, causing their 98 
relocalization and thus down-regulating their functionality, or even by mimicking RF substrates (5). In 99 
the case of HCMV, viral regulatory proteins (such as IE1p72, pp71, and others) mediate an efficient 100 
evasion from the antiviral state instituted by ND10, either by means of proteasomal degradation or by 101 
disrupting the host’s subnuclear structure (6, 22).  102 
In this study, we investigated the mechanisms used by HCMV to evade IFI16 restriction activity. 103 
We observed that starting from 72-96 hours post-infection (hpi), nuclear levels of IFI16 protein started 104 
to decrease in the nucleus and gradually increased in the cytoplasm of infected cells where it 105 
relocalized to the virus assembly complex (AC), as shown by its colocalization with the viral structural 106 
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proteins gB and pp65. Finally, through the use of immunogold electron microscopy and coprecipitation 107 
experiments, we provide evidence indicating that IFI16 eventually transits into the maturing virions 108 
embedded in the outer tegument layer. In conclusion, these data suggest that in order to overcome the 109 
restriction activity of IFI16, HCMV may stimulate its subcellular relocalization from the nucleus to the 110 
viral AC, followed by its inclusion into mature virions.  111 
 112 
MATERIALS AND METHODS 113 
Cells, viruses, and DNA constructs. Low-passage human embryonic lung fibroblasts (HELF) and 114 
human embryo kidney 293 cells (HEK 293) (Microbix Biosystems Inc.) were cultured in Eagle’s 115 
minimal essential medium (Life Technologies Italia) supplemented with 10% fetal calf serum (FCS, 116 
Sigma-Aldrich). Low passage human umbilical vein endothelial cells (HUVECs) were grown in 117 
Endothelial cell growth medium-2 (EGM-2) (Lonza) supplemented with 2% Fetal Bovine Serum and 118 
1% Penicillin-Streptomycin solution (Sigma-Aldrich) as previously described (23). The HCMV 119 
laboratory strain AD169 (ATCC-VR538) and the HCMV clinical isolate derivative VR1814 were 120 
propagated and titrated as previously described (21, 24). UV-inactivated AD169 was prepared using a 121 
double pulse of UV-B light (1.2 J/cm2). The mutant HCMV (AD169) BAC213 (ΔUL97/GFP+) was 122 
produced as previously described (25, 26). siRNA UL97 and siRNA CTRL were purchased from 123 
SIGMA and electroporated at a final concentration of 300 nM. Plasmids expressing WT and DN forms 124 
of Vps4A (pBJ-Vps4AWT and pBJ-Vps4AE228Q, respectively) were obtained as previously described 125 
(27, 28). 126 
Antibodies and reagents. Primary antibodies were obtained from various sources, as shown in 127 
Supplementary Table S1. Conjugated antibodies were as follow: fluorescein-isothiocyanate (FITC)- 128 
anti-rabbit (Sigma-Aldrich), Texas Red-anti-mouse and anti-rabbit (Invitrogen S.A.); horseradish 129 
peroxidase (HRP)-anti-mouse, HRP-anti-rabbit (GE Healthcare). The chemicals used in this study 130 
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were: Gö6976 (inhibitor of serine/threonine protein kinases, particularly pUL97 and PKC; Calbiochem) 131 
(29); phosphonoformic acid (PFA, Foscarnet) and Ganciclovir (HCMV inhibitors, Sigma-Aldrich). 132 
Cell Viability Assay. Cells were seeded at a density of 1x104/well in a 96-well culture plate. After 24 133 
hours, cells were treated with different doses (from 0.5 to 5 μM) of Gö6976. 72 hours after treatment, 134 
cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 135 
(MTT) (Sigma-Aldrich) method. 136 
Quantitative Real-Time RT-PCR. Real-time quantitative reverse transcription-PCR (RT-PCR) 137 
analysis was performed on an Mx 3000 P apparatus (Stratagene). Total RNA was extracted with the 138 
NucleoSpin RNA kit (Macherey-Nagel) and 1 µg was retrotranscribed using the Revert-Aid H-Minus 139 
FirstStrand cDNA Synthesis Kit (Fermentas). Reverse-transcribed cDNAs were amplified in duplicate 140 
using Brilliant Sybr green QPCR master mix (Fermentas) for IFI16; the housekeeping gene 141 
Glyceraldehyde-3-phosphate dehydrogenase (GADPH) was used to normalize for variations in cDNA 142 
levels (Primer sequences: IFI16 forward: ACTGAGTACAACAAAGCCATTTGA; IFI16 reverse: 143 
TTGTGACATTGTCCTGTCCCCAC; GADPH forward: TCGGAGTCAACGGATTTGGTC; GADPH 144 
reverse: CGTTCTCAGCCTTGACGGTG). 145 
ChIP assay. Similar to the method published by Cristea et al. (11) and Li et al. (18). HELFs were 146 
infected with HCMV at an MOI of 5. At 6 hpi, cells were cross-linked with 1% paraformaldehyde for 147 
15 min and then processed for ChIP assay, using the EpiTect ChIP OneDay Kit (Qiagen) according to 148 
the manufacturer’s instruction. Anti-IFI16 antibody (5 μg) was used to pull down the protein-chromatin 149 
complexes. Rabbit IgG was used as a negative control. The immunoprecipitated DNA was recovered 150 
by column purification and analyzed by PCR using HCMV or human specific primers (primer 151 
sequences are available on request).  152 
Immunofluorescence microscopy. Immunofluorescence analysis was performed as previously 153 
described (30) using the appropriate dilution of primary antibodies (Table S1) for 1h at room 154 
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temperature (RT), followed by 1h with secondary antibodies in the dark at RT. Nuclei were 155 
counterstained with DAPI where indicated. Finally, coverslips were mounted with Vectashield 156 
mounting medium (Vector Laboratories Ltd,) and cells visualized with a Leica TCS SP2 confocal 157 
microscope, equipped with a UV laser (351–364 nm) and argon–krypton laser (457–675 nm) (Leica 158 
Microsystems S.r.l.), using a 63X oil immersion objective NA 1.4. Fluorescence in-situ hybridization 159 
was combined with immunofluorescence by performing the hybridization first as described below and 160 
then incubating the coverslips with primary and secondary antibodies. 161 
Fluorescence in-situ hybridization (FISH). HCMV-infected HELFs were grown on glass slides, fixed 162 
as described above, and permeabilized with 0.5% Triton-X100 for 20 min at 4°C. The probe used for 163 
FISH was a BAC DNA containing the entire HCMV genome (a gift from Jay Nelson, Oregon Health 164 
and Science University), labeled using the biotin-nick translation system (Roche Diagnostics GmbH) 165 
according to the manufacturer’s protocol. The probe was added to the hybridization buffer (0.2 ng/µl 166 
yeast t-RNA, 50% formamide, 15% SSC, 0.1% Tween-20) at a concentration of 2 ng/µl, then incubated 167 
at 72°C for 5 min in order to denature the probe and the sample. Hybridization was continued overnight 168 
at 37°C in a humidified chamber. After stringent washing, cells were blocked with 10% normal goat 169 
serum. HCMV probes were then detected using the tyramide signal amplification procedure, according 170 
to manufacturer’s instructions (PerkinElmer Life and Analytical Sciences Inc.). Images were analyzed 171 
using a confocal laser scanning microscope.  172 
Immunoprecipitation assay. Uninfected cells or cells infected with HCMV (MOI of 1) for different 173 
times were washed and lysed in RIPA buffer. 200 μg of protein were incubated with 2 μg 174 
immunoprecipitating or control antibody for 1h at room temperature with rotation and the immune 175 
complexes were collected using protein G–Sepharose (Sigma-Aldrich). The Sepharose beads were 176 
pelleted and washed three times with RIPA buffer, boiled with sample buffer, and resolved on an 8% 177 
SDS-PAGE gel to assess the protein binding by Western blot.  178 
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Western blot analysis. Nuclear and cytoplasmic extracts were collected using the Nuclear Extract Kit 179 
(Active Motif), according to the manufacturer’s instructions, and subjected to immunoblot analysis as 180 
previously described (31). Briefly, an equal amount of cell extracts were fractionated by 181 
electrophoresis on sodium dodecyl sulfate polyacrylamide gels and transferred to Immobilon-P 182 
membranes (Millipore). After blocking, membranes were incubated overnight at 4°C with the 183 
appropriate primary antibodies. Membranes were then washed and incubated for 1h at RT with 184 
secondary antibodies. Proteins were detected using an enhanced chemiluminescence detection kit 185 
(Thermo SCIENTIFIC). 186 
Scanning densitometry of the bands was performed using Quantity One software, version 4.6.9 (Bio-187 
Rad Laboratories S.r.l.). Background values were subtracted from each calculated value. 188 
Virion purification and viral protein extraction. Virus containing media was collected at 192h post-189 
infection (MOI of 1), centrifuged at 3000 rpm for 10 min to remove large cellular debris, and then 190 
filtered using a Filtropur 0.45 (Sarstedt). To pellet viral particles, the media was then centrifuged at 191 
13000 g for 2h at 4°C in a Beckman SW32 Ti rotor. The viral pellet was resuspended in PBS1X and 192 
centrifuged in a 20-41-70% discontinuous sucrose gradient composed of the following steps: 0.5 ml 193 
60% (w/w) sucrose, 1.5 ml 41% sucrose, and 1 ml 20% sucrose. Sucrose solutions were made in 194 
PBS1X. Following centrifugation overnight at 130000 g at 4°C, using a Beckman SW40 Ti rotor, the 195 
virus containing band was removed from the gradient and lysed with 50 mM Tris HCl pH 6.8, 2% SDS, 196 
for 30 min at 4°C. After heating for 10 min at 95°C and clarification, the viral protein extract was 197 
collected. 198 
In vitro kinase assay. The kinase activity of FLAG-tagged pUL97 was determined in vitro after 199 
immunoprecipitation of the kinase from whole-cell lysates of HEK 293 cells, previously electroporated 200 
using a MicroPorator MP-100 (Digital BioTechnology), according to the manufacturer’s instructions (a 201 
single 1200 V pulse, 30 ms pulse width). The following UL97 expression constructs were employed: 202 
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pcDNA-UL97-M2, pcDNA-UL97(181-707)-M2, and pcDNA-UL97(1-595)-M2 (25). 203 
Immunoprecipitates were subsequently pelleted, washed, and subjected to in vitro kinase assay reaction 204 
[2.5 µCi of γ-32P ATP (Amersham Biosciences)] at 30°C for 30 min, as previously described (26), in 205 
the presence of the recombinant full-length IFI16 as substrate (5 µg). Following incubation, samples 206 
were separated by SDS-PAGE, transferred to Immobilon-P membranes (Millipore), and processed for 207 
autoradiography and immunoblotting.  208 
Immunogold labeling of isolated viral particles. For transmission electron microscopic analysis, 209 
samples were allowed to adsorb onto carbon and formvar-coated grids and fixed in 4% 210 
paraformaldehyde. Grids were then washed with PBS and water and, when appropriate, samples were 211 
permeabilized using 0.2% Triton. The grids were stained with primary antibodies followed by gold-212 
labeled secondary antibodies in the presence of 10% human serum (32). Grids were then negatively 213 
stained using 0.5% uranyl acetate for 1 min. Images were captured using a CM 10 electron microscope 214 
(Philips).  215 
 216 
RESULTS 217 
IFI16 colocalizes with HCMV genome early during infection. IFI16 has previously been shown to 218 
interact with HSV-1 as well as HCMV DNA early during infection (13, 15, 17, 18, 33, 34). To confirm 219 
that endogenous IFI16 interacts with viral DNA during natural HCMV infection, HELFs were mock 220 
infected or infected with HCMV for 12h. Combined immunofluorescence and FISH analysis was 221 
performed using IFI16 antibodies and a probe for the HCMV genome. In mock infected cells, IFI16 222 
was distributed into defined spots, which appear to reorganize following HCMV infection and 223 
colocalize with the HCMV-DNA (Fig. 1A). The colocalization of IFI16 with the viral genome is 224 
reinforced by Z stack images, generated by 3D reconstruction of confocal images to improve 225 
colocalization analysis (Fig. 1A, far right pictures). Consistent with FISH analysis and in accord with 226 
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the results reported by Li et al. (18), ChIP assays at 6 hpi demonstrated that endogenous IFI16 227 
specifically recognizes virus DNA loci, but not host chromosomal DNA (Fig. 1B). Altogether, these 228 
results are compatible with the proposed role of IFI16 as a nuclear sensor for HCMV DNA. 229 
HCMV relocalizes IFI16 nuclear protein into the cytoplasm. IFI16 is typically located within the 230 
nucleus (11, 15, 35, 36), but it translocates to the cytoplasm following infection with HSV-1 (12, 13, 15, 231 
17, 34), KSHV (14, 16), or EBV (10). To determine the subcellular localization of IFI16 during early 232 
and late infection with HCMV, two different approaches were adopted: Western blot analysis and 233 
immunofluorescence (IF). In the first case, HELFs, synchronized by serum starvation to increase 234 
infection efficiency (37, 38), were mock infected or infected with HCMV at an MOI of 1; they were 235 
then fractionated into nuclear and cytoplasmic components. The purity of the nuclear and cytoplasmic 236 
fractions was monitored by Western blot for the presence of TATA binding protein (TBP) and tubulin, 237 
respectively (Fig. 1C). IEA protein labeling was used to assess HCMV infection by Western blot (Fig. 238 
S1, panel A). In mock infected cells, IFI16 was exclusively nuclear (Fig. 1C, lane 1). Notably, at 24 hpi, 239 
HCMV-infected cells showed an increase in nuclear IFI16 that peaked at 48h then decreased at 96 hpi 240 
and almost disappeared at 144 hpi (Fig. 1C, lane 2-6). However, at 48 hpi IFI16 was also detected at 241 
appreciable levels in the cytoplasm of HCMV-infected cells and gradually increased at later time points 242 
(Fig. 1C, lane 10). Consistent with the Western blot results, RT-PCR analysis confirmed that HCMV 243 
infection upregulates IFI16 also at the mRNA level (~2 fold between 12 and 24 hours of HCMV vs. 244 
mock infected cells) (Fig. S1, panel B). 245 
These results demonstrate that HCMV induces the cytoplasmic translocation of IFI16 early on during 246 
infection. In apparent contrast to our results, Li et al. (18) and Cristea et al. (11) found that endogenous 247 
IFI16 remained nuclear during early HCMV infection. In our study, nuclear delocalization started from 248 
96 hpi, a time point not examined by Cristea et al. (11) and Li et al. (18). Moreover, IFI16 nuclear 249 
egress into the cytoplasm was only observed when synchronized cell cultures were used. This condition 250 
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was created to increase virus infection efficiency. Thus, considering the different post infection time 251 
points analyzed and the virus MOI employed, the discrepancies between our results the results reported 252 
by the other investigators can be easily explained.  253 
To gain deeper insight into the nuclear disappearance of IFI16, a detailed analysis using 254 
confocal microscopy at time points ranging from 12 hpi to 144 hpi was performed. As shown in Fig. 1, 255 
panel D, and Fig. S1, panel C, all infected cells positive for IEA staining showed the nuclear presence 256 
of IFI16 during the first 12 hpi. In contrast, between 72 and 96 hpi, IFI16 became undetectable in the 257 
nucleus of the majority of the cells, accompanied by its appearance in the cytoplasm. Consistent with 258 
the Western blot outcome, the IFI16 nuclear decline in infected cells was accompanied by the 259 
appearance of IFI16 in the cytoplasm, specifically in the compartment that overlapped with the virus 260 
AC, as shown by its colocalization with the viral glycoprotein gB. To verify that the signal observed in 261 
the AC was specific for IFI16 and not due to rabbit IgG binding to HCMV-encoded Fc receptor-like 262 
proteins (39, 40), the staining was performed after blocking the Fc receptors using 10% HCMV 263 
negative human serum prior to the addition of the specific rabbit IgG, as described in Buchkovich et al. 264 
(41). Similar results were obtained using monoclonal anti-IFI16 antibodies (Santa Cruz) (data not 265 
shown), which have also been used in other studies to demonstrate the nuclear export of IFI16 (14, 15). 266 
Finally, to exclude the possibility that IFI16 nuclear egression was limited to HELF cells 267 
infected by the AD169 strain, IF analysis was performed on human umbilical vein endothelial cells 268 
(HUVEC) infected with the endotheliotropic VR1814 strain. A similar pattern of IFI16 relocalization 269 
from the nucleus accompanied by its appearance in the AC compartment was observed, demonstrating 270 
that IFI16 nuclear delocalization is related to HCMV infection (Fig. S1 panel D).  271 
HCMV early/late proteins induce the nucleo-cytoplasmic relocalization of IFI16. The observation 272 
that the relocalization of IFI16 protein into the cytoplasm sharply increases from 48 hpi, accompanied 273 
by its gradual nuclear disappearance, suggests that an early or late viral protein(s) is(are) responsible 274 
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for driving IFI16 into the cytoplasm. To test this possibility, HELFs were infected with UVB-275 
inactivated HCMV, or with wild-type HCMV in the presence of 100 µM phosphonoformic acid (PFA) 276 
or 100 µM ganciclovir (GCV). To confirm that the infection was successfully established, FISH 277 
staining was performed (Fig. S2). As shown in Fig. 2, all treatments blocked IFI16 nucleo-cytoplasmic 278 
translocation. Since treatment with PFA or GCV inhibits viral DNA synthesis and the accumulation of 279 
early-late and late viral proteins to different extents, an early-late or late HCMV gene product is likely 280 
to be responsible for IFI16 subcellular relocalization.  281 
HCMV pUL97 contributes to the nucleo-cytoplasmic translocation of IFI16. To gain insight into 282 
the mechanism responsible for the HCMV-induced nuclear reduction and relocalization of IFI16 into 283 
the cytoplasm, we focused on the recently described HCMV nuclear egress complex (NEC) composed 284 
of viral and cellular proteins (25, 26, 42). In this context, the viral protein kinase pUL97 is known to 285 
play an important role by phosphorylating and reorganizing nuclear lamins A/C, a step required for the 286 
nuclear egress of viral capsids (26, 43). We therefore hypothesized that pUL97 might also be involved 287 
in the regulation of IFI16 nucleo-cytoplasmic relocalization. To test this, HELFs were infected with a 288 
GFP-tagged recombinant UL97 deletion mutant BAC (BAC ΔUL97), or AD169 (AD169 UL97+) as 289 
control (25, 43), and used for immunostaining at 32 days post infection (dpi) or 96 hpi, respectively. 290 
The lack of production of pUL97 by BAC ΔUL97 was confirmed by immunofluorescence staining 291 
(data not shown). The choice to perform the experiments at different time points was due to the delayed 292 
replication kinetics of viruses lacking a functional pUL97 kinase compared to the wild-type strain, as 293 
previously reported (25, 44, 45). As shown in Fig. 3A, many AD169 UL97+-infected cells showed 294 
IFI16 relocalization into the cytoplasm. In contrast, cells infected with a UL97 deletion mutant BAC 295 
(BAC ΔUL97) displayed IFI16 nuclear accumulation (Fig. 3A, panel 1). To gain further supporting 296 
evidence of the specific involvement of pUL97 in the cytoplasmic relocalization of IFI16, HELFs were 297 
electroporated with a mixture of three different small interfering RNAs targeting the UL97 gene 298 
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(siRNA UL97) or with scrambled control siRNA (siRNA CTRL). Twenty-four hours later, cells were 299 
infected with HCMV for a duration of 72h. The siRNA-mediated knock-down reduced the expression 300 
of pUL97 protein by approximately 90-95%, as indicated by Western blot analysis (Fig. S3, panel A). 301 
As shown in Fig. 3A (panel 2), and consistent with the results of the BAC mutant experiments, 302 
inhibition of pUL97 expression prevented IFI16 nuclear egress compared to infected cells pre-treated 303 
with control siRNA. Moreover, treating infected cells with the pUL97 inhibitor Gö6976 (2 μM, (26)) 304 
strongly suppressed IFI16 relocalization (Fig. 3A, panel 3), in agreement with the results of previous 305 
studies (26, 29). No such effect was observed when cells were treated with vehicle control (DMSO). To 306 
exclude the possibility that the Gö6976 inhibitor might influence the observed effect independent of 307 
viral infection, the MTT assay was used to examine and quantify its effect on HELF survival (Fig. S3, 308 
panel B). Finally, to investigate whether pUL97 alone is sufficient to induce IFI16 nuclear egress in the 309 
absence of other viral gene products, the protein was transfected into HELFs. In contrast to what we 310 
observed following virus infection, IFI16 retained its nuclear localization 72h after protein 311 
electroporation, indicating that pUL97 alone, in the absence of viable and functional virus, is not 312 
sufficient to trigger the relocalization of IFI16 into the cytoplasm (Fig. S3, panel C).  313 
To investigate the interplay between IFI16 and pUL97, total protein extracts from HELFs 314 
infected with HCMV for 96h were used for coimmunoprecipitation with anti-IFI16 or the appropriate 315 
control antibodies. Precipitates were then immunostained with a monoclonal anti-pUL97 antibody. As 316 
shown in Fig. 3B (left panel), virus pUL97 indeed binds to IFI16. This interaction is specific as no 317 
migrating bands were present when coprecipitation was performed using control antibodies. The 318 
presence of pUL97 in all protein extracts was monitored by the staining of INPUT (non-319 
immunoprecipitated whole cell extract) control samples (Fig. 3B). To confirm further the specificity of 320 
the interaction, coimmunoprecipitation and immunoblotting experiments were performed in reverse 321 
order, i.e., anti-UL97 was used for immunoprecipitation and anti-IFI16 for immunoblotting (Fig. 3B, 322 
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right panel). In line with previous results, a band corresponding to IFI16 was detectable when protein 323 
extracts were immunoprecipitated with an antibody against virus pUL97.  324 
 The interaction between IFI16 and pUL97 suggested that IFI16 might be directly 325 
phosphorylated by pUL97 kinase. To address this hypothesis, we performed an in vitro kinase assay 326 
(26) using wild-type and mutant pUL97, immunoprecipitated from lysates of transiently transfected 327 
HEK 293 cells, and incubated with highly purified recombinant IFI16 protein as substrate. IFI16 328 
phosphorylation was exclusively detectable for wild-type pUL97 and catalytically active pUL97 [N-329 
terminally truncated pUL97-(181-707)] (Fig. 3C, lanes 1 and 2, respectively), whereas an inactive C-330 
terminally truncated version (pUL97-1-595) (lane 3) did not produce a phosphorylation signal. 331 
IFI16 co-localizes with the viral AC following nuclear egress. It has been proposed that HCMV 332 
acquires its final envelope from the trans-Golgi network (TGN) or from TGN-derived particles (28, 42). 333 
In addition, many cellular markers, like those of early, recycling, and late endosomes, as well as the 334 
Endosomal Sorting Complex Required for Transport (ESCRT) and several viral tegument and envelope 335 
proteins, including gB, all localize to the AC (28). Since IFI16 staining appears to overlap with the AC, 336 
as shown by confocal analysis, we wanted to gain insights into the fate of IFI16 following nuclear 337 
egression. We performed an immunofluorescence assay at 96 hpi using anti-IFI16 antibodies together 338 
with antibodies recognizing the virion envelope protein gB, vacuolar protein sorting-4A (Vps4A, a 339 
component of the ESCRT machinery), or TGN46 (a marker of the trans-Golgi network) (Fig. 4A). As 340 
shown in Fig. 1D and 4A (confocal Z stack images), a high level of IFI16 colocalization could be 341 
detected with viral gB, Vps4A, and TGN46. These results strongly suggest that IFI16 mislocalizes out 342 
of the nucleus and associates with AC-containing virion particles.  343 
To define better the relationship between IFI16 and ESCRT components, total protein extracts 344 
from HELFs infected with HCMV for 96h were immunoprecipitated with anti-Vps4A or control 345 
antibodies, and immunoblotted with polyclonal anti-IFI16 antibodies. As shown in Fig. 4B (upper 346 
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panel), no interaction between Vps4A and IFI16 was observed in mock-infected cells. In contrast, 347 
HCMV infection induced a strong interaction between Vps4A and IFI16 as shown by the co-IP 348 
reactions. The same results were obtained in reverse order (Fig. 4B, lower panel). Vps4A induction by 349 
HCMV was also evident in the very same total protein extracts. Finally, no bands were detected when 350 
cell extracts were immunoprecipitated with control antibodies. Overall, these results indicate that there 351 
might be a connection between the egress of viral proteins from the nucleus and the mislocalization of 352 
IFI16 protein into the AC.  353 
Functional significance of the IFI16-Vps4 interaction. To evaluate the impact of dysfunctional 354 
MVBs on IFI16 localization, we used a previously described construct expressing a dominant negative 355 
Vps4A (27, 28). HELF cells were transfected with FLAG-tagged pBJ5-Vps4AE228Q or the 356 
corresponding wild-type form pBJ5-Vps4AWT and 24 hours later infected with HCMV. The 357 
transfection efficiency of HELFs is low (~20%), such that only the FLAG-expressing subpopulation of 358 
cells was studied. Confocal microscopy at 72 hpi (96% HCMV-positive cells, data not shown) 359 
demonstrated that in the pBJ5-Vps4E228Q-transfected cells IFI16 remains strictly nuclear (Fig. 4C, lower 360 
panel) in all of the infected cells. In contrast, in cells transfected with the wild-type vector, we observed 361 
that IFI16 mislocalizes to the cytoplasm (upper panels), confirming the dependence of IFI16 362 
mislocalization on functional MVB biogenesis, which serves as a platform for HCMV 363 
envelopment/egress.  364 
Immunogold labeling of IFI16 in purified HCMV particles. The colocalization of IFI16 and viral 365 
gB in the AC opened up the possibility that IFI16 may be incorporated into viral particles during 366 
maturation. To investigate this possibility, HCMV virions were fractionated by sucrose gradient from 367 
supernatants of HELFs infected at an MOI of 1 for 192 hours, and analyzed by Western blot for the 368 
viral proteins IEA, UL44, and pp65, and cellular proteins IFI16 and p53 (the latter is translocated into 369 
the cytoplasm during HCMV infection) (46). As shown in Fig. 5A, pp65 and IFI16 were detected in 370 
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highly purified virions, indicating their incorporation. The specificity of IFI16 incorporation into viral 371 
particles was supported by the finding that neither of the nonstructural viral proteins, such as IEA, 372 
UL44 nor cellular p53, were identified by Western blot analysis. Importantly, total cell extracts from 373 
mock- or HCMV-infected HELFs were included in order to estimate the levels of IFI16 induction by 374 
HCMV infection. The presence of IFI16 in purified virions was confirmed by coimmunoprecipitation 375 
experiments using anti-pp65 antibodies. As shown in Fig. 5B, IFI16 indeed interacted with the HCMV 376 
tegument protein pp65. Consistent with our results, Li et al. (18) have recently demonstrated that early 377 
during infection, pp65 associates with IFI16 by interacting with its pyrin domain, inhibiting its 378 
subsequent immune signaling (11, 18).  379 
To investigate further the incorporation of IFI16 into mature virions, we labeled purified virus 380 
particles with IFI16-specific antibodies followed by gold-conjugated secondary antibodies and 381 
analyzed them by means of electron microscopy. The integrity of the purified virions was further 382 
verified by negative staining that showed two classes of spherical enveloped particles: 200 nm diameter 383 
HCMV virions and larger structures corresponding to dense bodies (DBs). The ratio of virions to DBs 384 
was about 1:2. The specificity of the immunogold labeling was assessed by omitting the primary 385 
antibody. The virus preparation was permeabilized or left unmasked, so that antibodies could recognize 386 
within the inner layers of the viral particles or on their surface, respectively. As shown in Fig. 5C, gB, 387 
used as a control, was observed in the outer envelope of the purified virions, while pp65 was present 388 
inside the viral particles. Altogether, these results demonstrate that a percentage of IFI16 protein 389 
becomes trapped within mature virions.   390 
 391 
DISCUSSION 392 
The importance of the role played by restriction factors in controlling viral infection is substantiated by 393 
the diverse mechanisms the viruses have evolved to antagonize it (47-49). We recently demonstrated 394 
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that the IFN-inducible protein IFI16 may act as a restriction factor for HCMV replication by down-395 
regulating viral early and late mRNA and protein expression (21). In this study, we examined how 396 
HCMV can overcome the antiviral activity of the nuclear restriction factor IFI16. Consistent with its 397 
property as a pathogenic DNA sensor, (10-14, 17-20, 33, 50), detailed kinetics studies exploiting 398 
immunofluorescence show that in the early phases of infection, IFI16 binds to viral DNA, also 399 
confirmed by FISH combined with Western blot analysis. These results are in line with previous 400 
studies showing that following HCMV infection IFI16 binds viral DNA and triggers the expression of 401 
antiviral cytokines via the STING-TBK1-IRF3 signaling pathway (18). 402 
During a late phase post infection, however, IFI16 levels decreases inside the nucleus and this is 403 
accompanied by a parallel increase in its presence in the cytoplasmic AC, as shown by Western blot 404 
and confocal microscopy analysis. This nucleo-cytoplasmic egress of IFI16 in HCMV-infected cells is 405 
driven, at least in part, by the viral protein kinase pUL97, which binds and phosphorylates nuclear 406 
IFI16. Subsequently, the IFI16-AC complex mediates its incorporation into newly assembled virions. 407 
IFI16 mislocalization and assembly into mature virions appears to be regulated by the ESCRT 408 
machinery through its sorting and trafficking into multivesicular bodies. 409 
Other studies have examined the effects of herpesvirus infection on IFI16 degradation. Orzalli 410 
et al. (15, 51) demonstrated that during HSV-1 infection, the viral nuclear ICP0 protein leads to IFI16 411 
degradation. Similarly, Johnson et al. (13) showed that HSV-1 specifically targets IFI16 for rapid 412 
proteasomal degradation later on post-infection. Interestingly, another herpesvirus, namely KSHV, 413 
which undergoes latency in endothelial cells, was not found to cause IFI16 degradation early on during 414 
infection, suggesting a relationship between virus replication/latency and IFI16 fate (13, 14).  415 
Although the egression of IFI16 from the nucleus into the cytoplasm following pathogenic or 416 
damaged DNA sensing has now been widely demonstrated, the mechanisms it relies on have not been 417 
clarified. Therefore, in the present study we sought to exploit the HCMV model in order to gain some 418 
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insight into the mechanisms underlying IFI16 mislocalization. The finding that IFI16 egress from the 419 
nucleus was first detected at 48 hpi and the fact that it could be blocked by pre-treating cells with 420 
inhibitors of viral L gene expression suggest that HCMV L genes may be responsible for IFI16 421 
mislocalization. During HCMV replication, DNA-filled capsids bud through the inner nuclear 422 
membrane (INM) and transit from the nucleus direct to the AC located in the cytoplasm close to the 423 
nuclear membrane (42). The HCMV-specific nuclear egress complex (NEC) is composed of both viral 424 
and cellular proteins, in particular protein kinases with the capacity to induce the destabilization of the 425 
nuclear lamina (43). The viral protein kinase pUL97, along with cellular protein kinase C (PKC), plays 426 
an important role by phosphorylating several types of nuclear lamins, events that lead to the 427 
reorganization of the proteinaceous network underlying the inner nuclear membrane and the egression 428 
of the DNA-filled capsids (26, 43, 52). By combining molecular-virological analyses with biochemical 429 
and pharmacological approaches we demonstrate that pUL97 binds and phosphorylates IFI16 in vitro, 430 
triggering its relocalization from the nucleus into the cytoplasm of HCMV-infected cells. This assertion 431 
is based on the finding that the lack of viral pUL97 expression (BAC ΔUL97) and/or the inhibition of 432 
its kinase activity substantially reduce IFI16 relocalization. Together with the observation that IFI16 is 433 
phosphorylated both in vitro and in HCMV infected cells by pUL97 kinase, our results demonstrate 434 
that one of the viral candidates responsible for IFI16 subcellular relocalization and the inhibition of its 435 
restriction activity could be pUL97. In HCMV infection, the transmembrane protein pUL50 anchors 436 
the NEC within the inner nuclear membrane and associates with core NEC components, such as pUL53. 437 
As a consequence, the NEC is able to recruit regulatory kinases, like pUL97, to disassemble the nuclear 438 
lamina and to facilitate nuclear capsid egression. As IFI16 has been shown to interact with pUL97, we 439 
can speculate that IFI16 might interact with further components of the NEC.  440 
Post-translational modification provides a possible means of regulating IFI16 subcellular 441 
localization. The acetylation and phosphorylation of different IFI16 motifs have been demonstrated to 442 
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regulate its subcellular localization in lymphocytes and macrophages (11, 34). In particular, acetylation 443 
of the nuclear localization sequence promotes the cytoplasmic accumulation of IFII6 by inhibiting its 444 
nuclear import (34). In HCMV-infected cells, IFI16 interacts with viral pUL97 and undergoes in vitro 445 
phosphorylation. Moreover, the nuclear accumulation of IFI16 can be observed upon treatment with 446 
Gö6976, an inhibitor of pUL97 phosphorylation (26, 29). Together, these results suggest that 447 
phosphorylation by pUL97 may regulate the relocalization of IFI16 from the nucleus to the cytoplasm. 448 
Although the replication of all herpesviruses includes nuclear and cytoplasmic maturation 449 
events, the AC is a unique feature of beta-herpesvirus-infected cells (53). Virus particles congregate in 450 
the AC during the late phases of infection (42), consistent with its important role in controlling final 451 
tegumentation, envelopment, and egress from the cell. Immunofluorescence analysis starting at 24 hpi 452 
demonstrates that IFI16 co-localizes outside the nucleus of infected cells in a structure that seems to be 453 
the AC. The AC was recognized based on the hallmark morphology of CMV-infected cells which 454 
consist of an enlargement of the nucleus that transforms into a kidney-shaped form, with the AC 455 
pressing against the newly formed depression in the nucleus (54). To confirm definitively the nature of 456 
the AC, confocal laser microscopy was performed using antibodies against host proteins of the MVBs 457 
included in the AC, such as the ATPase Vps4A involved in the ESCRT pathway, the trans-Golgi 458 
network marker TGN46, and the viral protein gB, known to colocalize to the AC during the late phase 459 
of HCMV infection. Moreover, using coimmunoprecipitation experiments we found that IFI16 460 
interacts with Vps4A upon HCMV infection. Overall, these results demonstrate that HCMV induces 461 
IFI16 to mislocalize to MVBs, where the virus undergoes final maturation.  462 
To provide a functional significance of the colocalization experiments, we evaluated the impact 463 
of inhibiting the final component of the ESCRT machinery, Vps4A, using a dominant negative mutant 464 
(Vps4AE228Q) known to impair MVB biogenesis and HCMV plaque formation (28). The nuclear 465 
retention of IFI16 in cells where MVB biogenesis was inhibited suggests a strict dependence of IFI16 466 
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subcellular localization on HCMV replication and designates Vps4A as a key player in the evasion 467 
mechanism employed by HCMV to escape IFI16.  468 
The presence of IFI16 in the AC and the lack of protein degradation in the late stages of 469 
infection could suggest that IFI16 is incorporated into the maturing virion particles. To investigate this 470 
possibility, we purified HCMV virions and applied Western blot and electron microscopy analysis to 471 
ascertain whether HCMV virions may actually contain the mislocalized IFI16. Intriguingly, Western 472 
blot analysis demonstrates the presence of IFI16, but not p53, in the viral protein extract. Moreover, the 473 
immunolocalization results confirmed the incorporation of IFI16 into purified virions, and in particular 474 
in the outer layer of the tegument in the proximity of pp65, as shown by co-precipitation experiments. 475 
This finding leans toward excluding the possibility that IFI16 non-specifically aggregates to virions 476 
during their maturation. Consistent with our results, previous studies based on mass spectrometry 477 
approaches have demonstrated the presence of at least 70 host cellular and 71 HCMV proteins in 478 
mature virions (55, 56). More recently, it has been demonstrated that HCMV may include both trans-479 
Golgi network and endosomal markers when undergoing final envelopment (32). Altogether, these 480 
findings raise some important questions. The first one asks how specific the inclusion of host proteins 481 
in HCMV virions is, since only a percentage of virus particles contain IFI16. The observation that 482 
IFI16, but not p53, another protein egressing from the nucleus during HCMV infection, is included in 483 
the virion, suggests that some mechanisms of selecting host proteins must exist. The second important 484 
question that needs addressing is whether HCMV includes IFI16 in the virion in order to evade its 485 
restriction activity. At the moment, no evidence exists suggesting a functional consequence of IFI16 486 
embedded within the viral particles, thus only speculations can be put forward. However, some 487 
observations may help to explain why the virus hijacks IFI16 and embeds it into the outer layer of the 488 
tegument. First, IFI16 triggers the activity of transcription factor NFκB that is needed in the first steps 489 
of HCMV infection (57, 58). Second, it has been demonstrated that pp65 (pUL83) triggers the 490 
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expression of the viral immediate-early promoter through its interaction with IFI16 protein (11, 18). 491 
Finally, overexpression of IFI16 up-regulates immediate-early protein expression during the first hours 492 
of infection (21). Altogether, these observations suggest that HCMV may hijack IFI16 in order to 493 
exploit its capacity to enhance the transcription of IE genes during the early steps of infection, followed 494 
by the relocalization of IFI16 into the cytoplasmic AC with the scope of concealing its restriction 495 
activity during the late steps of infection.  496 
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FIGURE LEGENDS 678 
FIG 1 Effect of HCMV infection on IFI16 localization. (A) The HCMV genome is recognized by 679 
IFI16 at early time points following infection. HELF cells were mock-infected (MOCK) or infected 680 
with HCMV (strain AD169, MOI of 2 PFU/cell), fixed in 1% paraformaldehyde at 12 hours post 681 
infection (hpi), and subjected to combined fluorescent in-situ hybridization (FISH) with a BAC DNA 682 
probe containing the entire HCMV genome (red) and immunofluorescence analysis (IFA) with anti-683 
IFI16 antibodies (green). Cell nuclei are visualized in blue. Images were taken by confocal microscopy, 684 
and the far right hand picture shows 3D image reconstruction of stacks of confocal images. At least five 685 
fields were digitally reconstructed to generate the 3D images for each condition; representative images 686 
are shown. (B) HELFs were infected at an MOI of 5 and processed for ChIP assays 6 hours later to test 687 
the association of endogenous IFI16 with HCMV and host DNA. (C) IFI16 accumulates in the 688 
cytoplasm of HCMV infected cells at late time points post infection. HELF cells were infected with 689 
HCMV at an MOI of 1 PFU/cell. Nuclear and cytoplasmic fractions were prepared at the indicated time 690 
points and subjected to Western blotting and subsequent densitometry for IFI16. Results were 691 
normalized to TBP and tubulin, respectively (*p<0.05, ** p<0.01, *** p< 0.001, one-way ANOVA 692 
followed by Bonferroni’s post test). (D) Kinetics of IFI16 sub-cellular localization upon HCMV 693 
infection. HELF cells were infected with HCMV at an MOI of 1 PFU/cell for the indicated time points 694 
and subjected to confocal microscopy analysis. IFI16 (green) and viral proteins (red) were visualized 695 
using primary antibodies followed by secondary antibody staining, in the presence of 10% human 696 
serum. Nuclei are visualized in blue. The far right hand picture of each panel shows a Z stack of 697 
confocal images, generating a 3D reconstruction, obtained as described in (A). 698 
FIG 2 HCMV inhibition blocks the mislocalization of IFI16. HELFs were infected with wild-type or 699 
UV-inactivated HCMV (1 PFU/cell; 1.2 J/cm2 for 2 pulses) and treated with phosphonoformic acid 700 
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(PFA, 100 µM) or Ganciclovir (GCV, 100 μM) as indicated. Cells were fixed 72h later in 1% 701 
paraformaldehyde and processed by immunofluorescence analysis for IFI16 (green) and gB (red).  702 
FIG 3 pUL97 mediates HCMV-induced IFI16 mislocalization. (A) pUL97 inhibition impairs IFI16 703 
nuclear egress. HELFs were treated as described in detail below and in the results section, fixed at the 704 
time points indicated below, and double stained with the appropriated antibodies. HELFs infected with 705 
a UL97 deletion mutant BAC (BAC ∆UL97) or with AD169 UL97+ as a control at an MOI of 1 706 
PFU/ml, were fixed and immunostained at 32 days or 96 hours post infection, respectively (panel 1); 707 
HELFs were electroporated with a mixture of three different small interfering RNAs targeting UL97 708 
(siRNA UL97) or with scrambled control siRNA (siRNA CTRL) and 24h later infected with HCMV at 709 
an MOI of 1 PFU/cell for 72h (panel 2); HCMV-infected HELFs were treated with the pUL97 inhibitor 710 
Gö6976 (2 µM) or with an equal volume of vehicle control (DMSO) and immunostained after 72h 711 
(panel 3). (B) IFI16 interacts with pUL97. Total cell protein extracts from HELFs infected with HCMV 712 
at an MOI of 1 for 96h were immunoprecipitated with polyclonal antibodies against IFI16 (left panel) 713 
or monoclonal antibodies against UL97 (right panel), and control antibody. Samples were then 714 
immunoblotted with antibodies for pUL97 and IFI16, respectively. Non-immunoprecipitated whole cell 715 
extract (INPUT) obtained from HCMV-infected cells was employed to normalize the proteins 716 
subjected to immunoprecipitation. (C) Phosphorylation of IFI16 by pUL97 in vitro. HEK 293 cells 717 
were transfected with wild-type pUL97 (lane 1), catalytically active pUL97 (N-terminally truncated 718 
pUL97-181-707) (lane 2), or inactive C-terminally truncated pUL97 (pUL97-1-595, lane 3). At 48h 719 
post-transfection, cells were lysed and subjected to immunoprecipitation (IP) with monoclonal 720 
antibodies for pUL97, followed by in vitro kinase reaction with recombinant IFI16 (rIFI16) as substrate. 721 
Labeled phosphorylation products were separated by SDS-PAGE and visualized by exposing the blots 722 
to autoradiography film (upper panel). Lysate control samples taken prior to immunoprecipitation were 723 
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used for Western blot analysis with the monoclonal antibodies for pUL97 to monitor the levels of 724 
expressed proteins (lower panel).  725 
FIG 4 HCMV infection induces IFI16 sorting into multivesicular bodies (MVBs). (A) IFI16 726 
colocalizes with components of MVBs and the ESCRT pathway in HCMV-infected cells. HELF cells 727 
were infected with HCMV at an MOI of 1 PFU/cell; 96 hours later cells were fixed, permeabilized, and 728 
co-stained with anti-IFI16, anti-TGN46, anti-Vps4A, and anti-HCMV glycoprotein gB antibodies. 729 
Nuclei were visualized in blue. Images were taken by confocal microscopy, and the far right hand panel 730 
shows a 3D image reconstruction of stacks of confocal images. At least five fields were digitally 731 
reconstructed for each condition and a representative image is shown. (B) IFI16 interacts with Vps4A 732 
in HCMV-infected cells. Total cell protein extracts obtained by HELFs treated as described above were 733 
immunoprecipitated with antibodies against Vps4A (upper panel) or IFI16 (lower panel), and the 734 
appropriate control antibody (CTRL). Immunoprecipitated samples and whole cell extracts (INPUT) 735 
were then immunoblotted using antibodies against Vps4A or IFI16. (C) Effect of blocking MVB 736 
biogenesis on IFI16 localization. HELF cells co-transfected with a construct expressing Vps4A 737 
(Vps4WT) or the mutated form Vps4AE228Q were infected with HCMV (MOI of 1 PFU/cell) 24 hours 738 
post transfection. Cells were fixed and photographed at 72 hpi. Vps4A was detected by anti-FLAG 739 
primary antibody (red) and IFI16 by the polyclonal anti-IFI16 antibody (green). Representative images 740 
were taken using 63X magnification. 741 
FIG 5 IFI16 is associated with purified HCMV particles. (A) HCMV particles (indicated as virions) 742 
were purified by sucrose gradient from supernatants of infected HELFs (192 hpi, MOI of 1) and 743 
analyzed by immunoblotting for the viral proteins IEA, UL44, and pp65, and the cellular proteins IFI16 744 
or p53. Total cell extract from MOCK- or HCMV-infected cells were included as controls. (B) IFI16 745 
interacts with pp65 in purified virions. HELFs were infected as described for panel A. Protein extracts 746 
were obtained from purified virions and immunoprecipitated with anti-pp65 (upper panel) or anti-IFI16 747 
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(lower panel) and the appropriate control antibodies (CTRL), and then immunoblotted with anti-IFI16 748 
or anti-pp65 antibodies, respectively. Non-immunoprecipitated whole cell extracts (INPUT) were 749 
immunoblotted with anti-IFI16 or anti-pp65 antibodies and employed to normalize the proteins 750 
subjected to immunoprecipitation. (C) Immunoelectron microscopy analysis of purified virions stained, 751 
in the presence of 10% human serum, for IFI16 and HCMV gB and pp65, or left unstained (secAb). 15 752 






FIG 1 Effect of HCMV infection on IFI16 localization. (A) The HCMV genome is recognized by 
IFI16 at early time points following infection. HELF cells were mock-infected (MOCK) or infected 
with HCMV (strain AD169, MOI of 2 PFU/cell), fixed in 1% paraformaldehyde at 12 hours post 
infection (hpi), and subjected to combined fluorescent in-situ hybridization (FISH) with a BAC 
DNA probe containing the entire HCMV genome (red) and immunofluorescence analysis (IFA) 
with anti-IFI16 antibodies (green). Cell nuclei are visualized in blue. Images were taken by confocal 
microscopy, and the far right hand picture shows 3D image reconstruction of stacks of confocal 
images. At least five fields were digitally reconstructed to generate the 3D images for each 
condition; representative images are shown. (B) HELFs were infected at an MOI of 5 and processed 
for ChIP assays 6 hours later to test the association of endogenous IFI16 with HCMV and host 
DNA. (C) IFI16 accumulates in the cytoplasm of HCMV infected cells at late time points post 
infection. HELF cells were infected with HCMV at an MOI of 1 PFU/cell. Nuclear and cytoplasmic 
fractions were prepared at the indicated time points and subjected to Western blotting and 
subsequent densitometry for IFI16. Results were normalized to TBP and tubulin, respectively 
(*p<0.05, ** p<0.01, *** p< 0.001, one-way ANOVA followed by Bonferroni’s post test). (D) 
Kinetics of IFI16 sub-cellular localization upon HCMV infection. HELF cells were infected with 
HCMV at an MOI of 1 PFU/cell for the indicated time points and subjected to confocal microscopy 
analysis. IFI16 (green) and viral proteins (red) were visualized using primary antibodies followed 
by secondary antibody staining, in the presence of 10% human serum. Nuclei are visualized in blue. 
The far right hand picture of each panel shows a Z stack of confocal images, generating a 3D 




FIG 2 HCMV inhibition blocks the mislocalization of IFI16. HELFs were infected with wild-type 
or UV-inactivated HCMV (1 PFU/cell; 1.2 J/cm
2
 for 2 pulses) and treated with phosphonoformic 
acid (PFA, 100 µM) or Ganciclovir (GCV, 100 µM) as indicated. Cells were fixed 72h later in 1% 
paraformaldehyde and processed by immunofluorescence analysis for IFI16 (green) and gB (red).  
 
 
FIG 3 pUL97 mediates HCMV-induced IFI16 mislocalization. (A) pUL97 inhibition impairs IFI16 
nuclear egress. HELFs were treated as described in detail below and in the results section, fixed at 
the time points indicated below, and double stained with the appropriated antibodies. HELFs 
infected with a UL97 deletion mutant BAC (BAC ∆UL97) or with AD169 UL97
+
 as a control at an 
MOI of 1 PFU/ml, were fixed and immunostained at 32 days or 96 hours post infection, 
respectively (panel 1); HELFs were electroporated with a mixture of three different small 
interfering RNAs targeting UL97 (siRNA UL97) or with scrambled control siRNA (siRNA CTRL) 
and 24h later infected with HCMV at an MOI of 1 PFU/cell for 72h (panel 2); HCMV-infected 
HELFs were treated with the pUL97 inhibitor Gö6976 (2 µM) or with an equal volume of vehicle 
control (DMSO) and immunostained after 72h (panel 3). (B) IFI16 interacts with pUL97. Total cell 
protein extracts from HELFs infected with HCMV at an MOI of 1 for 96h were immunoprecipitated 
with polyclonal antibodies against IFI16 (left panel) or monoclonal antibodies against UL97 (right 
panel), and control antibody. Samples were then immunoblotted with antibodies for pUL97 and 
IFI16, respectively. Non-immunoprecipitated whole cell extract (INPUT) obtained from HCMV-
infected cells was employed to normalize the proteins subjected to immunoprecipitation. (C) 
Phosphorylation of IFI16 by pUL97 in vitro. HEK 293 cells were transfected with wild-type pUL97 
(lane 1), catalytically active pUL97 (N-terminally truncated pUL97-181-707) (lane 2), or inactive 
C-terminally truncated pUL97 (pUL97-1-595, lane 3). At 48h post-transfection, cells were lysed 
and subjected to immunoprecipitation (IP) with monoclonal antibodies for pUL97, followed by in 
vitro kinase reaction with recombinant IFI16 (rIFI16) as substrate. Labeled phosphorylation 
products were separated by SDS-PAGE and visualized by exposing the blots to autoradiography 
film (upper panel). Lysate control samples taken prior to immunoprecipitation were used for 
Western blot analysis with the monoclonal antibodies for pUL97 to monitor the levels of expressed 




FIG 4 HCMV infection induces IFI16 sorting into multivesicular bodies (MVBs). (A) IFI16 
colocalizes with components of MVBs and the ESCRT pathway in HCMV-infected cells. HELF 
cells were infected with HCMV at an MOI of 1 PFU/cell; 96 hours later cells were fixed, 
permeabilized, and co-stained with anti-IFI16, anti-TGN46, anti-Vps4A, and anti-HCMV 
glycoprotein gB antibodies. Nuclei were visualized in blue. Images were taken by confocal 
microscopy, and the far right hand panel shows a 3D image reconstruction of stacks of confocal 
images. At least five fields were digitally reconstructed for each condition and a representative 
image is shown. (B) IFI16 interacts with Vps4A in HCMV-infected cells. Total cell protein extracts 
obtained by HELFs treated as described above were immunoprecipitated with antibodies against 
Vps4A (upper panel) or IFI16 (lower panel), and the appropriate control antibody (CTRL). 
Immunoprecipitated samples and whole cell extracts (INPUT) were then immunoblotted using 
antibodies against Vps4A or IFI16. (C) Effect of blocking MVB biogenesis on IFI16 localization. 
HELF cells co-transfected with a construct expressing Vps4A (Vps4WT) or the mutated form 
Vps4AE228Q were infected with HCMV (MOI of 1 PFU/cell) 24 hours post transfection. Cells were 
fixed and photographed at 72 hpi. Vps4A was detected by anti-FLAG primary antibody (red) and 





FIG 5 IFI16 is associated with purified HCMV particles. (A) HCMV particles (indicated as virions) 
were purified by sucrose gradient from supernatants of infected HELFs (192 hpi, MOI of 1) and 
analyzed by immunoblotting for the viral proteins IEA, UL44, and pp65, and the cellular proteins 
IFI16 or p53. Total cell extract from MOCK- or HCMV-infected cells were included as controls. 
(B) IFI16 interacts with pp65 in purified virions. HELFs were infected as described for panel A. 
Protein extracts were obtained from purified virions and immunoprecipitated with anti-pp65 (upper 
panel) or anti-IFI16 (lower panel) and the appropriate control antibodies (CTRL), and then 
immunoblotted with anti-IFI16 or anti-pp65 antibodies, respectively. Non-immunoprecipitated 
whole cell extracts (INPUT) were immunoblotted with anti-IFI16 or anti-pp65 antibodies and 
employed to normalize the proteins subjected to immunoprecipitation. (C) Immunoelectron 
microscopy analysis of purified virions stained, in the presence of 10% human serum, for IFI16 and 
HCMV gB and pp65, or left unstained (secAb). 15 nm gold conjugated secondary antibody was 
used to detect proteins. Scale bar, 100 nm.  
 
 
 
 
